Lipo-PGE1治疗家兔肠系膜静脉血栓形成的实验研究
|
摘要
第一部分:凝血酶注射法建立家兔肠系膜静脉血栓形成模型
目的探讨凝血酶注射法建立家兔肠系膜静脉血栓形成模型的方法及其特点。方法家兔36只随机分为3组,每组12只。肠系膜前静脉分支注射凝血酶,A组80单位/1毫升,B组40单位/1毫升,C组注射生理盐水1毫升。观测血栓形成时间和周围静脉血D-D二聚体值变化。结果AB两组均可建立稳定的肠系膜静脉血栓形成模型,广泛性血栓形成时间分别为15.6±2.0分钟和22.3±2.5分钟,有显著性差异(P<0.001)。血栓形成前AB两组周围静脉血D-D二聚体分别为68.4±5.7ng/ml vs 72.7±6.4ng/ml,血栓形成后为209.0±24.0ng/ml vs 215.4±17.6ng/ml,组间无显著性差异,组内有统计学显著性差异(P<0.001)。单纯肠系膜前静脉阻断30分钟不形成血栓。结论凝血酶注射法可建立稳定的家兔肠系膜血栓形成模型,凝血酶用量为80单位/1毫升。
第二部分:Lipo PGE1对家兔肠系膜静脉血栓形成模型D-二聚体值的影响
目的通过分析脂质微球化前列腺素E1(Lipo-PGE1)对家兔肠系膜静脉血栓形成(MVT)模型周围静脉血D-二聚体值的影响,探讨Lipo-PGE1用于治疗急性MVT的可行性。方法30只家兔平均分为ABC三组,AB两组建立肠系膜静脉血栓形成模型,治疗方案分别为,A组“帕肝素+Lipo-PGE1+5%葡萄糖生理盐水”,B组“帕肝素+5%葡萄糖生理盐水”。C组为空白对照组,采取“帕肝素+5%葡萄糖生理盐水”。分别于模型组的5个时间点,手术前(T1)、血栓形成后1小时(T2)、治疗后2小时(T3)、治疗后4小时(T4)、治疗后6小时(T5),检测周围静脉血D-二聚体值。实验结束后检查小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况。结果A组T3~T5周围血D-二聚体值分别为247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml;B组T3~T5周围血D-二聚体值分别为231.9±14.1 ng/ml,228.7±12.4 ng/ml,224.6±12.6 ng/ml。T3时间点A组与B组D-二聚体值无显著性差异(P>0.05),T4和T5时间点A组与B组之间D-二聚体值分别有显著性差异(P<0.001)。C组T3~T5时间点均显著低于AB组相应D-二聚体值(P<0.001)。A组小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况均优于B组(P<0.05)。结论Lipo-PGE1可显著增强家兔肠系膜血栓形成模型纤溶活性,使其周围静脉血D-二聚体值增高,且随着时间的延长而持续升高。对家兔肠系膜静脉血栓形成模型有潜在治疗价值。
第三部分:Lipo PGE1联合小剂量尿激酶对家兔肠系膜静脉血栓形成模型D-二聚体值的影响
目的分析Lipo-PGE1联合小剂量尿激酶对家兔肠系膜静脉血栓形成模型D-二聚体值的影响,探讨其对于肠系膜静脉血栓治疗中的价值。方法实验动物家兔30只随机分为ABC三组,每组10只,建立肠系膜静脉血栓模型。按照不同治疗方案干预:A组“帕肝素+ Lipo-PGE1”,B组“帕肝素+小剂量尿激酶”+5%葡萄糖生理盐水,C组“帕肝素+小剂量尿激酶+Lipo-PGE1”。分别于模型组的5个时间点,手术前(T1)、血栓形成后1小时(T2)、治疗后2小时(T3)、治疗后4小时(T4)、治疗后6小时(T5),检测周围静脉血D-二聚体值。实验结束后观察小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况。结果A组在T3~T5时间点D-二聚体值分别为,247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml;B组在T3~T5时间点D-二聚体值分别为,305.7±13.8 ng/ml,262.0±7.5 ng/ml,259.0±5.1 ng/ml,;C组在T3~T5时间点D-二聚体值分别为,304.4±21.4 ng/ml,345.0±10.4 ng/ml,359.2±10.3 ng/ml。C组在治疗后4小时和6小时D-二聚体值均明显高于A组和B组,有显著性差异(P<0.001),B组在治疗2小时D-二聚体值迅速升高后于治疗后4小时和6小时平稳下降。A组和C组治疗效果(小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况等指标)优于B组(P<0.01),而A组和C组肠系膜血栓溶解率和病理评分无显著性差异(P>0.05)。结论Lipo-PGE1可明显增强小剂量尿激酶对家兔肠系膜静脉血栓形成模型的体内纤溶活性,且效果持续增强。对血栓溶解率和病理评分的影响研究有待延长观测时间。
第四部分:Lipo-PGE1联合帕肝素治疗肠系膜静脉血栓形成:病例分析及文献回顾
目的探讨Lipo-PGE1联合帕肝素治疗急性肠系膜静脉血栓的可行性。方法分析2006年1月至2008年4月我院收治的5例经Lipo-PGE1联合帕肝素治疗的急性肠系膜静脉血栓病例,结合相关文献复习分析其诊断、治疗和预后。结果3例临床治愈,复查彩超2例血栓全部消失,1例部分消失。2例因肠梗阻和回盲部肿瘤剖腹探查,术中确认肠系膜静脉血栓消失。结论Lipo-PGE1联合帕肝素治疗急性肠系膜静脉血栓可行,为进一步验证其治疗效果,需进行多中心、大样本合作研究。
Part One : Injecting Thrombase to Establish the Model of Mesenteric Venous Thrombosis in Rabbits
Objective To investigate the method and characters of injecting thrombase to establish the model of mesenteric venous thrombosis(MVT) in rabbits. Method We grouped 36 rabbits into 3 units randomly, 12 per group and injected thrombase in mesenteric venous tributary 80u/1ml in group A, 40u/1ml in group B, and made group C to be the comparison group in which 1ml normal saline was used only. The time of thrombogenesis and the variation of D-Dimer in peripheral venous blood were surveyed. Results Both group A and B could establish stabile MVT models. The time of extensive thrombus formation was 15.6±2.0 minutes in group A and 22.3±2.5 minutes in group B separately, and there was significant difference between them (P<0.001). D-Dimer in peripheral venous blood before thrombogenesis was 68.4±5.7ng/ml vs 72.7±6.4ng/ml, and after thrombogenesis was 209.0±24.0ng/ml vs 215.4±17.6ng/ml, and there was no significant difference between the groups (P>0.05), and there was significant difference in each group (P<0.001). No thrombosis occurred in group C which was blocked without injecting thrombase. Conclusion Injecting thrombase with 80u/1ml is a feasible method to establish the model of rabbits with mesenteric vein thrombosis.
Part Two: The Effect of Using Lipo-PGE1 on D-dimer Value in Rabbits’Mesenteric Vein Thrombosis
Objective To investigate the possibility of using Lipo-PGE1 to treat acute mesenteric vein thrombosis by analyzing the variation of the D-dimer drew from the peripheral vein belongs to the acute rabbit MVT models injected Lipo-PGE1. Method We made 30 rabbits into A, B,C groups equally .Group A and Group B were established as MVT models. The treatment plan of group A was Parnaparin+Lipo-PGE1+5%GNS, group B was Parnaparin+5%GNS. The group C as blank comparison was treated with Parnaparin+5%GNS. Detecting the D-dimer quantitation from the peripheral vein in the model groups at the moments of preoperative, 1h after the the thrombogenesis, and 2h, 4h, 6h after the treatment, named T1-T5 respectively. Observing the modified Chiu’s scores and the thrombolysis statement after the experiment. Results The D-dimer results of group A T3-T5 were 247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml separately; while group B T3-T5 were 231.9±14.1 ng/ml,228.7±12.4 ng/ml,224.6±12.6 ng/ml separately. There was no significant difference at the moment of T3 between group A and group B (P>0.05) and had significant difference at the moment of T4 and T5 (P<0.001). The D-dimer quantitation of group C was significantly small than group A and B (P<0.001). The thrombolysis rate and pathologic scores in group A was significantly better than group B (P<0.05). Conclusion Lipo-PGE1 could significantly enhance the thrombolysis activity of the rabbits’MVT models and make the peripheral venous D-dimer quantitation keep rising with time lasting. It has potential therapeutic value to deal with the rabbits’MVT.
Part Three: The Effect of Using Lipo-PGE1 Combined Small Dose Urokinase on D-dimer Value in Rabbits’Mesenteric Vein Thrombosis
Objective To investigate the treatment value to mesenteric venous thrombosis by analyzing the variation of plasma D-dimer according to use Lipo-PGE1 combined small dose urokinase to treat rabbits’MVT. Method We made 30 rabbits into groupA,B,C randomly and equally, then established the MVT models. Each group received different treatment plan as intervention: parnaparin+lipo-PGE1 for group A; parnaparin+small dose UK+5%G/NS for group B and parnaparin+ small dose UK+lipo-PGE1 for group C. Detecting the peripheral vein plasma D-dimer quantitation 5 times in the model groups seperately at the moment of 1h before operation(T1),1h after the thrombosis formed(T2), and 2h、4h、6h after treated(T3). Observing the modified Chiu’s scores and the thrombolysis statement after the experiment. Result The D-dimer quantitation of group A at T3-T5 were 247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml; the same of group B were 305.7±13.8 ng/ml,262.0±7.5 ng/ml,259.0±5.1 ng/ml and group C were 304.4±21.4 ng/ml,345.0±10.4 ng/ml,359.2±10.3 ng/ml. D-dimer quantitation of group C at T4 and T5 were obviously higher than group A and group B, with significant difference exist((P<0.001).In group B, D-dimer was rising rapidly at the moment of 2h after the treatment and smoothly decreasing at the moment of 4h-6h. The therapeutic effect in group A and C, the thrombolysis rate and pathologic scores are better than group B, and there was no significant difference of the thrombolysis rate and pathologic scores among the group A and C(p>0.05). Conclusion Lipo-PGE1 could enhance the thrombolysis activity obviously by using small dose UK to treat rabbit MVT models. The effect was persisting. Long time observation was needed to investigate the effect of thrombolysis rate.
Part Four: Using Lipo-PGE1 Combined with Parnaparin to Treat Mesenteric Vein Thrombosis: Case Analysis and Literature Review
Objective: To investigate the possibility of using Lipo-PGE1 to treat acute mesenteric vein thrombosis in human cases. Method: We analyzed the clinic data of five patient who were diagnosed as acute mesenteric thrombosis and treated with Lipo-PGE1 Combined with Parnaparin from January 2006 to April 2008, and investigated the diagnosis, therapeutic method and prognosis aided with a literature review. Result: Three cases were cured clinically, and two of them was proved as a complete thrombolysis by doppler color ultrasonography, the other one as a partial thrombolysis. Two cases were received laparotomy because of ileus and tumor located in ileocecal junction, and observed no mesenteric venouse thrombosis in operation. Conclusion: Lipo-PGE1 combined with Parnaparin can be used in the treatment of mesenteric venous thrombosis. Advanced evidence must be offered by a multi center prospective and randomized clinic study with great large sample.
目的探讨凝血酶注射法建立家兔肠系膜静脉血栓形成模型的方法及其特点。方法家兔36只随机分为3组,每组12只。肠系膜前静脉分支注射凝血酶,A组80单位/1毫升,B组40单位/1毫升,C组注射生理盐水1毫升。观测血栓形成时间和周围静脉血D-D二聚体值变化。结果AB两组均可建立稳定的肠系膜静脉血栓形成模型,广泛性血栓形成时间分别为15.6±2.0分钟和22.3±2.5分钟,有显著性差异(P<0.001)。血栓形成前AB两组周围静脉血D-D二聚体分别为68.4±5.7ng/ml vs 72.7±6.4ng/ml,血栓形成后为209.0±24.0ng/ml vs 215.4±17.6ng/ml,组间无显著性差异,组内有统计学显著性差异(P<0.001)。单纯肠系膜前静脉阻断30分钟不形成血栓。结论凝血酶注射法可建立稳定的家兔肠系膜血栓形成模型,凝血酶用量为80单位/1毫升。
第二部分:Lipo PGE1对家兔肠系膜静脉血栓形成模型D-二聚体值的影响
目的通过分析脂质微球化前列腺素E1(Lipo-PGE1)对家兔肠系膜静脉血栓形成(MVT)模型周围静脉血D-二聚体值的影响,探讨Lipo-PGE1用于治疗急性MVT的可行性。方法30只家兔平均分为ABC三组,AB两组建立肠系膜静脉血栓形成模型,治疗方案分别为,A组“帕肝素+Lipo-PGE1+5%葡萄糖生理盐水”,B组“帕肝素+5%葡萄糖生理盐水”。C组为空白对照组,采取“帕肝素+5%葡萄糖生理盐水”。分别于模型组的5个时间点,手术前(T1)、血栓形成后1小时(T2)、治疗后2小时(T3)、治疗后4小时(T4)、治疗后6小时(T5),检测周围静脉血D-二聚体值。实验结束后检查小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况。结果A组T3~T5周围血D-二聚体值分别为247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml;B组T3~T5周围血D-二聚体值分别为231.9±14.1 ng/ml,228.7±12.4 ng/ml,224.6±12.6 ng/ml。T3时间点A组与B组D-二聚体值无显著性差异(P>0.05),T4和T5时间点A组与B组之间D-二聚体值分别有显著性差异(P<0.001)。C组T3~T5时间点均显著低于AB组相应D-二聚体值(P<0.001)。A组小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况均优于B组(P<0.05)。结论Lipo-PGE1可显著增强家兔肠系膜血栓形成模型纤溶活性,使其周围静脉血D-二聚体值增高,且随着时间的延长而持续升高。对家兔肠系膜静脉血栓形成模型有潜在治疗价值。
第三部分:Lipo PGE1联合小剂量尿激酶对家兔肠系膜静脉血栓形成模型D-二聚体值的影响
目的分析Lipo-PGE1联合小剂量尿激酶对家兔肠系膜静脉血栓形成模型D-二聚体值的影响,探讨其对于肠系膜静脉血栓治疗中的价值。方法实验动物家兔30只随机分为ABC三组,每组10只,建立肠系膜静脉血栓模型。按照不同治疗方案干预:A组“帕肝素+ Lipo-PGE1”,B组“帕肝素+小剂量尿激酶”+5%葡萄糖生理盐水,C组“帕肝素+小剂量尿激酶+Lipo-PGE1”。分别于模型组的5个时间点,手术前(T1)、血栓形成后1小时(T2)、治疗后2小时(T3)、治疗后4小时(T4)、治疗后6小时(T5),检测周围静脉血D-二聚体值。实验结束后观察小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况。结果A组在T3~T5时间点D-二聚体值分别为,247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml;B组在T3~T5时间点D-二聚体值分别为,305.7±13.8 ng/ml,262.0±7.5 ng/ml,259.0±5.1 ng/ml,;C组在T3~T5时间点D-二聚体值分别为,304.4±21.4 ng/ml,345.0±10.4 ng/ml,359.2±10.3 ng/ml。C组在治疗后4小时和6小时D-二聚体值均明显高于A组和B组,有显著性差异(P<0.001),B组在治疗2小时D-二聚体值迅速升高后于治疗后4小时和6小时平稳下降。A组和C组治疗效果(小肠粘膜病理改良Chiu氏评分、肠系膜静脉血栓溶解情况等指标)优于B组(P<0.01),而A组和C组肠系膜血栓溶解率和病理评分无显著性差异(P>0.05)。结论Lipo-PGE1可明显增强小剂量尿激酶对家兔肠系膜静脉血栓形成模型的体内纤溶活性,且效果持续增强。对血栓溶解率和病理评分的影响研究有待延长观测时间。
第四部分:Lipo-PGE1联合帕肝素治疗肠系膜静脉血栓形成:病例分析及文献回顾
目的探讨Lipo-PGE1联合帕肝素治疗急性肠系膜静脉血栓的可行性。方法分析2006年1月至2008年4月我院收治的5例经Lipo-PGE1联合帕肝素治疗的急性肠系膜静脉血栓病例,结合相关文献复习分析其诊断、治疗和预后。结果3例临床治愈,复查彩超2例血栓全部消失,1例部分消失。2例因肠梗阻和回盲部肿瘤剖腹探查,术中确认肠系膜静脉血栓消失。结论Lipo-PGE1联合帕肝素治疗急性肠系膜静脉血栓可行,为进一步验证其治疗效果,需进行多中心、大样本合作研究。
Part One : Injecting Thrombase to Establish the Model of Mesenteric Venous Thrombosis in Rabbits
Objective To investigate the method and characters of injecting thrombase to establish the model of mesenteric venous thrombosis(MVT) in rabbits. Method We grouped 36 rabbits into 3 units randomly, 12 per group and injected thrombase in mesenteric venous tributary 80u/1ml in group A, 40u/1ml in group B, and made group C to be the comparison group in which 1ml normal saline was used only. The time of thrombogenesis and the variation of D-Dimer in peripheral venous blood were surveyed. Results Both group A and B could establish stabile MVT models. The time of extensive thrombus formation was 15.6±2.0 minutes in group A and 22.3±2.5 minutes in group B separately, and there was significant difference between them (P<0.001). D-Dimer in peripheral venous blood before thrombogenesis was 68.4±5.7ng/ml vs 72.7±6.4ng/ml, and after thrombogenesis was 209.0±24.0ng/ml vs 215.4±17.6ng/ml, and there was no significant difference between the groups (P>0.05), and there was significant difference in each group (P<0.001). No thrombosis occurred in group C which was blocked without injecting thrombase. Conclusion Injecting thrombase with 80u/1ml is a feasible method to establish the model of rabbits with mesenteric vein thrombosis.
Part Two: The Effect of Using Lipo-PGE1 on D-dimer Value in Rabbits’Mesenteric Vein Thrombosis
Objective To investigate the possibility of using Lipo-PGE1 to treat acute mesenteric vein thrombosis by analyzing the variation of the D-dimer drew from the peripheral vein belongs to the acute rabbit MVT models injected Lipo-PGE1. Method We made 30 rabbits into A, B,C groups equally .Group A and Group B were established as MVT models. The treatment plan of group A was Parnaparin+Lipo-PGE1+5%GNS, group B was Parnaparin+5%GNS. The group C as blank comparison was treated with Parnaparin+5%GNS. Detecting the D-dimer quantitation from the peripheral vein in the model groups at the moments of preoperative, 1h after the the thrombogenesis, and 2h, 4h, 6h after the treatment, named T1-T5 respectively. Observing the modified Chiu’s scores and the thrombolysis statement after the experiment. Results The D-dimer results of group A T3-T5 were 247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml separately; while group B T3-T5 were 231.9±14.1 ng/ml,228.7±12.4 ng/ml,224.6±12.6 ng/ml separately. There was no significant difference at the moment of T3 between group A and group B (P>0.05) and had significant difference at the moment of T4 and T5 (P<0.001). The D-dimer quantitation of group C was significantly small than group A and B (P<0.001). The thrombolysis rate and pathologic scores in group A was significantly better than group B (P<0.05). Conclusion Lipo-PGE1 could significantly enhance the thrombolysis activity of the rabbits’MVT models and make the peripheral venous D-dimer quantitation keep rising with time lasting. It has potential therapeutic value to deal with the rabbits’MVT.
Part Three: The Effect of Using Lipo-PGE1 Combined Small Dose Urokinase on D-dimer Value in Rabbits’Mesenteric Vein Thrombosis
Objective To investigate the treatment value to mesenteric venous thrombosis by analyzing the variation of plasma D-dimer according to use Lipo-PGE1 combined small dose urokinase to treat rabbits’MVT. Method We made 30 rabbits into groupA,B,C randomly and equally, then established the MVT models. Each group received different treatment plan as intervention: parnaparin+lipo-PGE1 for group A; parnaparin+small dose UK+5%G/NS for group B and parnaparin+ small dose UK+lipo-PGE1 for group C. Detecting the peripheral vein plasma D-dimer quantitation 5 times in the model groups seperately at the moment of 1h before operation(T1),1h after the thrombosis formed(T2), and 2h、4h、6h after treated(T3). Observing the modified Chiu’s scores and the thrombolysis statement after the experiment. Result The D-dimer quantitation of group A at T3-T5 were 247.5±10.5ng/ml,259.1±9.6ng/ml,273.6±11.9 ng/ml; the same of group B were 305.7±13.8 ng/ml,262.0±7.5 ng/ml,259.0±5.1 ng/ml and group C were 304.4±21.4 ng/ml,345.0±10.4 ng/ml,359.2±10.3 ng/ml. D-dimer quantitation of group C at T4 and T5 were obviously higher than group A and group B, with significant difference exist((P<0.001).In group B, D-dimer was rising rapidly at the moment of 2h after the treatment and smoothly decreasing at the moment of 4h-6h. The therapeutic effect in group A and C, the thrombolysis rate and pathologic scores are better than group B, and there was no significant difference of the thrombolysis rate and pathologic scores among the group A and C(p>0.05). Conclusion Lipo-PGE1 could enhance the thrombolysis activity obviously by using small dose UK to treat rabbit MVT models. The effect was persisting. Long time observation was needed to investigate the effect of thrombolysis rate.
Part Four: Using Lipo-PGE1 Combined with Parnaparin to Treat Mesenteric Vein Thrombosis: Case Analysis and Literature Review
Objective: To investigate the possibility of using Lipo-PGE1 to treat acute mesenteric vein thrombosis in human cases. Method: We analyzed the clinic data of five patient who were diagnosed as acute mesenteric thrombosis and treated with Lipo-PGE1 Combined with Parnaparin from January 2006 to April 2008, and investigated the diagnosis, therapeutic method and prognosis aided with a literature review. Result: Three cases were cured clinically, and two of them was proved as a complete thrombolysis by doppler color ultrasonography, the other one as a partial thrombolysis. Two cases were received laparotomy because of ileus and tumor located in ileocecal junction, and observed no mesenteric venouse thrombosis in operation. Conclusion: Lipo-PGE1 combined with Parnaparin can be used in the treatment of mesenteric venous thrombosis. Advanced evidence must be offered by a multi center prospective and randomized clinic study with great large sample.
引文
1. Kumar S, Starr MG, Kamah PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683-1688.
2. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1911 to 1984. Surgery 1987; 101: 383-388.
3. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
4. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
5. Zhang J, Duan ZQ, Song QB, et al. Acute mesenteric venous thrombosis: a better outcome achieved through improved imaging techniques and a changed policy of clinical management. Eur J Vasc Endovasc Surg. 2004;28(3):329-34.
6. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg. 2001; 34:673-9.
7. Salamah SMA, Mirza SM. Acute mesenteric venous thrombosis: management controversies. JK-Practitioner. 2004; 11(4):242-247
8. Grieshop RJ, Dalsing MC, Cikrit DF, Lalka SG, Sawchuk A. Acute mesenteric venous thrombosis. Revisited in a time of diagnosis clarity. Am Surg 1991;57:573-7.
9. Harward TR, Green D, Bergan JJ, Rizzo RJ, Yao JST. Mesenteric venous thrombosis. J Vasc Surg 1989;9:328-33.
10. Rhee RY, Gloviczki P, Mendonca CT, Petterson TM, Serry RD, Sarr MG, et al. Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg 1994;20:688-97.
11. Klempnauer J, Grothues F, Bektas H, Pichlmayr R. Results of portal thrombectomy and splanchnic thrombolysis for the surgical management of acute mesentericoportal thrombosis. Br J Surg 1997;84:129-32.
12. Levy PJ, Krausz MM, Manny J. Acute mesenteric ischemia: improved results—a retrospective analysis of ninety-two patients. Surgery 1990;107:372-80.
13. Inderbitzi R, Wagner HE, Seiler C, Stirnemann P, Gertsch P. Acute mesenteric ischemia. Eur J Surg 1992;158:123-6.
14. Haglund U. Gut ischemia. Gut 1994;35(1 Suppl):S73-6.
15. Levi M, D?rffle-Melly J, Johnson GJ, et al. Usefulness and limitations of animal models of venous thrombosis. Thromb Haemost. 2001; 86(5):1331-3.
16. Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006; 12(8): 1165-1174
17. Elliot JW. The operative relief of gangrene of intestine due to occlusion of the mesenteric vessels. Ann Surg 1895;21:9-23.
18. Warren S, Eberhard TP. Mesenteric venous thrombosis. Surg Gynecol Obstet 1935;61:102-21.
19. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology. 1982;82:358-72.
20. Rhee RY, Gloviczki P.Mesenteric venous thrombosis. Surg Clin North Am. 1997 Apr;77(2):327-38.
21. Boley SJ, Kaleya RN, Brandt LJ. Mesenteric venous thrombosis. Surg Clin North Am 1992;72:183-201.
22. Acosta S, Ogren M, Sternby NH, et al. Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. J Vasc Surg. 2005 Jan;41(1):59-63.
23. Kramer CM, Budoff MJ, Fayad ZA, et al. ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. J Am Coll Cardiol. 2007;50:1097-1114.
24. Taourel PG, Deneuville M, Pradel JA, et al. Acute mesenteric ischemia: diagnosis with contrast-enhanced CT. Radiology. 1996;199:632-636.
25. Bradbury MS, Kavanagh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. RadioGraphics. 2002;22:527-541.
26. Kirkpatrick IDC, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. Radiology. 2003;229:91-98.
27. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004:1078-1090.
28. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1920-1940.
29. Kearon C. Natural History of Venous Thromboembolism. Circulation. 2003; 107: I-22-I-30.
30. Tovey C, Wyatt S. Diagnosis, investigation, and management of deep vein thrombosis. BMJ. 2003; 326: 1180-1184.
31. Anderson FA, Spencer FA. Risk Factors for Venous Thromboembolism. Criculation. 2003; 107: I-9-I-16.
32. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107: I-4-I-8.
33. Segal JB, Streiff MB, Hofman LV, et al. Management of venous thromboembolism a systematic review for a practice guideline. Ann Intern Med. 2007; 146: 211-222.
34. Hirsh J, O’Donnell M, Eikelboom JW. Beyond Unfractionated Heparin and Warfarin Current and Future Advances. Criculation. 2007; 116: 552-560.
35. Valji K, Bookstein JJ. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Radiology. 1993;186(3):873-6.
36. Aruva MR, Daviau J, Sharma SS, et al. Imaging thromboembolism with fibrin-avid 99mTc-peptide: evaluation in swine. J Nucl Med. 2006;47(1):155-62.
37. Wojewódzka-Zelezniakowicz M, Chabielska E, Mogielnicki A, et al. Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats. J Physiol Pharmacol. 2006;57(2):231-45.
38. Rosenfield AT, Zeman RK, Cronan JJ, et al. Ultrasound in experimental and clinical renal vein thrombosis. Radiology. 1980;137(3):735-41.
39. Korninger C, Matsuo O, Suy R, et al. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest. 1982 ;69(3):573-80.
40. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect ofmolecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest. 1983;71(2):368-76.
41. Rich NM, Hobson RW, Collins GJ, et al. The effect of acute popliteal venous interruption. Ann Surg. 1976;183(4):365-8.
42. Biemond BJ, Levi M, Coronel R, et al. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1995;91(4):1175-81.
43. Yokota K, Yamashita A, Oda M. Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis. Jpn J Pharmacol. 1995;68(2):201-6.
44. Minnema MC, Friederich PW, Levi M, et al.Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest. 1998 ;101(1):10-4.
45. Biemond BJ, Friederich PW, Koschinsky ML, et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation. 1997;96(5):1612-5.
46. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood. 1997;89(4):1270-8.
47. Biemond BJ, Friederich PW, Levi M, et al. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation. 1996 1;93(1):153-60.
48. Nakase H, Heimann A, Kempski O. Alterations of regional cerebral blood flow and oxygen saturation in a rat sinus-vein thrombosis model. Stroke. 1996;27(4):720-7; discussion 728.
49. Hennan JK, Hong TT, Shergill AK, et al. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther. 2002;301(3):1151-6.
50. Kang SG, Chung H, Hyon JY. Experimental preretinal neovascularization by laser-induced thrombosis in albino rats. Korean J Ophthalmol. 1999 Dec;13(2):65-70.
51. Schaller B, Graf R, Wienhard K, et al. A new animal model of cerebral venousinfarction: ligation of the posterior part of the superior sagittal sinus in the cat. Swiss Med Wkly. 2003 ;133(29-30):412-8.
52. Di Domenico S, Bovio G, Gelli M, et al. Cavo-portal transposition in rat: a new simple model. BMC Surg. 2007;7:18.
53. Chauhan AK, Kisucka J, Lamb CB, et al. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109(6):2424-9.
54. Narawane NM, Phadke AY, Shah SK, et al. Jejunal stricture complicating acute mesenteric venous thrombosis secondary to protein C deficiency and factor V Leiden gene mutation. Indian J Gastroenterol. 2000;19(2):79-80.
55. Green D, Ganger DR, Blei AT. Protein-C deficiency in splanchnic venous thrombosis. Am J Med. 1987; 82:171.
56. Olson JF, Steuber CP, et al. Functional deficiency of protein C associated with mesenteric venous thrombosis and splenic infarctioin. Am J Pediatr Hematol Oncol.1991; 139(2): 168.
57. De Stefano V, Leone G, et al. Mesenteric vein thrombosis in protein S congenital deficiency. Thromb Res. 1990;57:935.
58. Broekmans AW, Van Rooyen W, et al. Mesenteric vein thrombosis as presenting manifestation of herediatary protein S deficiency. Gastroenterology. 1987;92:240.
59. Maung R, Kelly JK, et al. Mesenteric venous thrombosis due tu antithrombin III deficiency. Arch Pthol Lab Med. 1998;112: 37.
60. Condat B, Pessione F, Denninger MH, et al. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32(3):466-470.
61. Marie I, Levesque H, Le Cam-Duchez V, et al. Mesenteric venous thrombosis revealing both factor II G20212A mutation and hyperhomocysteinemia related to pernicious anemia. Gastroenterology. 2000;118(1):237-8.
62. Hassan HA.Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol. 1999;29(1):90-5.
63. Schneiderman DJ, Cello IP. Intestinal ischemia and infarction associated with oralcontraceptives. West J Med. 1986;77:350
64. Hassan HA, Raufman JP.Mesenteric venous thrombosis. South Med J. 1999;92 (6):558-62.
65. Bradbury MS, Kavanagh PV, Chen MY, et al. Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies. J Comput Assist Tomogr. 2002;26:392-404
66. Parkeer HH, Bynoe RP, Nottingham JM. Thrombosis of the portal venous system after splenectomy for trauma. J Trauma. 2003;54:193-196
67. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70: 126-132
68. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therpy. N ENGL J MED. 2006, 355(17): 1780-9.
69. Heim SW, Schectman JM, Siadaty MS, et al. D-dimer testing for deep venous thrombosis: a metaanalysis. Clinical Chemistry. 2004, 50(7): 1136-1147.
70. Ombandza-Moussa E, Samama MM, Horellou MH, et al. Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode. Int Angiol. 2003; 22(4):364-9.
71. Eichinger S, Minar E, Bialonczyk C. et al. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA. 2003; 290:1071-1074.
72. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007; 5: 63-73.
73.靳毅,邢辉,王晓蓓. D-二聚体测定在血栓性疾病诊疗中的临床应用.中华医学杂志. 2007,87(32):2278-2280.
74.王克俊,荆蕊平,耿海燕等. D-二聚体定量测定在AMI溶栓治疗检测中的应用.放射免疫学杂志. 2007,20(1): 30-31.
75.丁向民,诸林海,张喜成等. D-二聚体在早期诊断急性肠系膜缺血的价值.中国现代普通外科进展. 2006, 9(6): 349-351
76.王利新,景在平,包俊敏等.急性深静脉血栓治疗前后血清D-二聚体的变化.外科理论与实践. 2005, 10(1): 80-82
77. G.Reber, H.Bounameaux, A.Peerier and P.de Moerloose. Performances of a new,automated latex assay for the exclusion of venous thromboembolism. Blood Coagulation and Fibrinolysis 2001,12:217-220.
78. Piedad Villla, Fernando Ferrando, Joesp Serra,et al.Quantification of D-dimer using a new fully automated assay: its application for the diagnosis of deep vein thrombosis. Haematologica 2000,85:520-524.
79. Teruko Fukuda, Hidetoshi Kasai, Takeo Kusano, et al. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. Thromb Res2007:120(5):695-701.
80. Robert C. Gosselin, John t. Owings, Joshua Kehoe, et al. Comparison of six D-dimer methods in patients suspected of deep vein thromosis. Blood Coagulation and Fibrinolysis2003,14(6):545-550
81.王振义,李家增,阮长耿等主编.血栓与止血:基础与临床.第三版.上海:上海科学技术出版社. 2004: 81-116.
1. Kumar S, Starr MG, Kamah PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683-1688.
2. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1991 to 1984. Surgery 1987; 101: 383-388.
3. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
4. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
5. Zhang J, Duan ZQ, Song QB, et al. Acute mesenteric venous thrombosis: a better outcome achieved through improved imaging techniques and a changed policy of clinical management. Eur J Vasc Endovasc Surg. 2004;28(3):329-34.
6. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
7. Rhee RY, Gloviczki P, Mendonca CT, et al. Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg 1994;20:688-97.
8. Ludwig DJ, Hauptmann E, Rossoff, et al. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg. 1999;30:511-554.
9. Antoch G, Taleb N, Hansen O, et al. Transarterial thrombolysis of portal and mesenteric vein thrombosis: a promising alternative to common therapy. Eur J Endovasc Surg. 2001;21:471-472.
10. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
11. Ludwig DJ, Hauptmann E, Rossoff, et al. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg. 1999;30:511-554.
12. Antoch G, Taleb N, Hansen O, et al. Transarterial thrombolysis of portal and mesenteric vein thrombosis: a promising alternative to common therapy. Eur J Endovasc Surg. 2001;21:471-472.
13. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
14. Salamah SMA, Mirza SM. Acute mesenteric venous thrombosis: management controversies. JK-Practitioner. 2004; 11(4):242-247
15. Kr?ger K, Buss C, Rudofsky G. Retrospective analysis of rt-PA thrombolysis combined with PGE1 in patients with peripheral arterial occlusions. Angiology. 2000; 51(5):377-84.
16. Valji K, Bookstein JJ. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Radiology. 1993; 186: 873-876.
17. Elliot JW. The operative relief of gangrene of intestine due to occlusion of the mesenteric vessels. Ann Surg 1895;21:9-23.
18. Warren S, Eberhard TP. Mesenteric venous thrombosis. Surg Gynecol Obstet 1935;61:102-21.
19. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology. 1982;82:358-72.
20. Rhee RY, Gloviczki P.Mesenteric venous thrombosis. Surg Clin North Am. 1997 Apr;77(2):327-38.
21. Boley SJ, Kaleya RN, Brandt LJ. Mesenteric venous thrombosis. Surg Clin North Am 1992;72:183-201.
22. Ernst CB, Stanley JC. Current therapy in vascular surgery. 4th ed. St. Louis: Mosby Inc.2001:693-697.
23. Naitove A, Weissman RE. Primary mesenteric venous thrombosis. Ann Surg. 1965;161:516-523.
24. Robin P, Gruel Y, Lang M, et al. Complete thrombosis of mesenteric vein occlusion with recombinant tissue-type plasminogen activator. Lancet. 1988;1(2):1391.
25.张健,段志泉,罗英伟等.急性肠系膜上静脉血栓形成的诊治分析.中华普通外科杂志. 2005;20(1): 21-23
26. Bilbao JI, Rodriguez-Cabello J, Longo J, et al. Portal thrombosis percutaneous transhepatic treatment with urokinase-a case report. Gastrointest Radiol. 1989;14:326-328
27. Rivitz SM, Geller SC, Hahn C, et al. Treatment of acute mesenteric venous thrombosiswith transjugular intramesenteric urokinase infusion. J Vasc Intervent Radiol. 1995;6:219-223.
28. Poplausky MR, Kaufman JA, Geller SG, et al. Mesenteric venous thrombosis treated with urokinase via the superior mesenteric artery. Gastroenterology. 1996; 110: 1633-1635
29. Choudhary AM, Grayer D, Nelson A, Roberts I. Mesenteric venous thrombosis. J Clin Gastroenterol 2000; 31:179-82.
30. Alam KM, Kayali AE, Mohammed AA, Galul RT. Superior mesenteric venous thrombosis: Riyadh Central Hospital experience. Kuwait Med J 2001; 33:18-21.
31. Ciecarelli O, Goffette P, Laterre PF, et al. Transjugular intrahepatic portosystemic shunt approach and local thrombolysis for treatment of early posttransplant portal vein thrombosis. Transplantation. 2001;72:159-161.
32. Smalling RW, Feld S, Ramanna N, et al. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation. 1995,15;92(4):935-43.
33. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophsiology of vascular disorders. Blood. 1998; 91(10): 3527-3561.
34. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved Issues in the Role of Cyclooxygenase-2 in Normal Physiologic Processes and Disease. Arch Intern Med. 2000;160: 913-920.
35. Hashiguchi M. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi 2004 124: 321-332.
36. Ozaki Masayuki, Ogata Masanori, Yokoyama Toru, et al. Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. Can J Anesth. 2005;52(2): 143-147.
37. Smalling RW, Feld S, Ramanna N, et al. Use of Nonsteroidal Antiinflammatory Drugs,An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007;115:1634-1642.
38. Vaughan DE, Plavin SR, Schafer AI, et al. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood. 1989 Apr;73(5):1213-7..
39. Terres W, Beythien C, Kupper W, et al. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis. Circulation. 1989; 79(6):1309-14.
40. Kerins DM, Shuh M, Kunitada S, et al. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. J Pharmacol Exp Ther. 1991; 257(1):487-92..
41. Coffman TM, Spurney RF, Mannon RB, et al. Thromboxane A2 modulates the fibrinolytic system in glomerular mesangial cells. Am J Physiol Renal Physiol. 1998; 275: 262-269.
42.李忠诚.尿激酶和凯时联合溶解深静脉血栓的临床研究.中国综合临床. 2002;1:36-38.
43.孙英信,时德,向志等.急性下肢深静脉血栓形成148例的治疗.第四军医大学学报. 2002; 5.
44.余翠琴.凯时的制剂特点.中国医院药学杂志. 2002;22(11): 691-692.
45. Heim SW, Schectman JM, Siadaty MS, et al. D-dimer testing for deep venous thrombosis: a metaanalysis. Clinical Chemistry. 2004, 50(7): 1136-1147.
46. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007; 5: 63-73.
47. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. Journal of Thrombosis and Thrombolysis.2008;25(1):37-44
48. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therpy. N ENGL J MED. 2006, 355(17): 1780-9.
49. Ombandza-Moussa E, Samama MM, Horellou MH, et al. Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode. Int Angiol. 2003; 22(4):364-9.
50. Eichinger S, Minar E, Bialonczyk C. et al. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA. 2003; 290:1071-1074.
51.靳毅,邢辉,王晓蓓. D-二聚体测定在血栓性疾病诊疗中的临床应用.中华医学杂志. 2007,87(32):2278-2280.
52.王克俊,荆蕊平,耿海燕等. D-二聚体定量测定在AMI溶栓治疗检测中的应用.放射免疫学杂志. 2007,20(1): 30-31.
53.丁向民,诸林海,张喜成等. D-二聚体在早期诊断急性肠系膜缺血的价值.中国现代普通外科进展. 2006, 9(6): 349-351
54.王利新,景在平,包俊敏等.急性深静脉血栓治疗前后血清D-二聚体的变化.外科理论与实践. 2005, 10(1): 80-82
55.王振义,李家增,阮长耿等主编.血栓与止血:基础与临床.第三版.上海:上海科学技术出版社. 2004: 3-154.
56. Haglund U. Gut ischaemia. Gut. 1994;supplement 1:73-76
57. Haglung U, Osterberg J. Local consequences of reperfusion in the gut. In: Piece A, Robert TM. Ischemia-Reperfusion injury. Blackwell Science, Oxford UK. 1999:65-69.
58. Haglund U, Bulkley GB, Granger DN. On the pathophysiology of intestinal ischemic injury. Acta Chir Scand 1987; 153: 321-4.
59. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. Arch Surg. 1970; 101: 478-83.
60. Park PO, Haglund U. Regeneration of small bowel mucosa after intestinal ischemia. Crit Care Med. 1992;20: 135-9.
61. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost. 2005 Apr;93(4):627-30.
62. Banerjee A, Chisti Y, Banerjee UC. Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv. 2004 Feb;22(4):287-307.
63. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 184-195.
64. White RA, Hollier LH. Vascular Surgery: Basic Science and Clinical Correlations. 2nd ed. Malden: Blackwell Publishing, 2005: 454-467.
1. Kumar S, Starr MG, Kamah PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683-1688.
2. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1991 to 1984. Surgery 1987; 101: 383-388.
3. Rhee RY, Gloviczki P, Mendonca CT. Mesenteric venous thrombosis: still a lethal disease in the 1990's. J Vas Surg 1994; 20:688-97.
4. Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006; 12(8):1165-74.
5.王玉琦,叶建荣主编.血管外科治疗学.上海:上海科学技术出版社. 2003: 1~14.
6. Banerjee A, Chisti Y, Banerjee UC. Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv. 2004 Feb;22(4):287-307.
7. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication? Thromb Haemost 2001;86:499-508
8. Sze DY, O'Sullivan GJ, Johnson DL,et al. Mesenteric and portal venous thrombosis treated by transjugular mechanical thrombolysis. AJR Am J Roentgenol. 2000; 175(3):732-4.
9. Kim HS, Patra A, Khan J, et al. Transhepatic Catheter-directed Thrombectomy and Thrombolysis of Acute Superior Mesenteric Venous Thrombosis. J Vasc Interv Radiol.2005; 16:1685-1691
10. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
11. Guglielmi A, Fior F, Halmos O, et al. Transhepatic fibrinolysis of mesenteric and portal vein thrombosis in a patient with ulcerative colitis: a case report. World J Gastroenterol.2005; 11(13):2035-8.
12. Kaplan JL, Weintraub SL, Hunt JP,et al. Treatment of superior mesenteric and portal vein thrombosis with direct thrombolytic infusion via an operatively placed mesenteric catheter. Am Surg. 2004; 70(7):600-4.
13. Lopera JE, Correa G, Brazzini A, et al. Percutaneous transhepatic treatment of symptomatic mesenteric venous thrombosis. J Vasc Surg. 2002; 36(5):1058-61.
14. Kim HS, Patra A, Khan J, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radiol. 2005; 16(12):1685-91.
15. Kr?ger K, Buss C, Rudofsky G. Retrospective analysis of rt-PA thrombolysis combined with PGE1 in patients with peripheral arterial occlusions. Angiology. 2000; 51(5):377-84.
16. Valji K, Bookstein JJ. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Radiology. 1993; 186: 873-876.
17. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
18. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
19. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
20.张健,王玉波,张强,等.急性肠系膜静脉血栓形成的非手术治疗.中国实用外科杂志. 2003,23(4): 220-221
21.张健,段志泉,罗英伟,等.急性肠系膜上静脉血栓形成的诊治分析.中华普通外科杂志. 2005,20(1): 21-23
22.王振义,李家增,阮长耿等主编.血栓与止血:基础与临床.第三版.上海:上海科学技术出版社. 2004: 809-824
23. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 184-195
24. White RA, Hollier LH. Vascular Surgery: Basic Science and Clinical Correlations. 2nd ed. Malden: Blackwell Publishing, 2005: 454-467
25. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost. 2005 Apr;93(4):627-30.
26. Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost. 1995 Jul;74(1):387-90.
27. Alpert JS. Importance of the pharmacological profile of thrombolytic agents in clinical practice. Am J Cardiol. 1991 Dec 5;68(16):3E-7E. Review.
28. Smalling RW, Feld S, Ramanna N, et al. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation. 1995,15;92(4):935-43.
29. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi. 2004;124(6): 321-332
30. Ozaki Masayuki, Ogata Masanori, Yokoyama Toru, et al. Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. Can J Anesth. 2005;52(2): 143-147.
31. Smalling RW, Feld S, Ramanna N, et al. Use of Nonsteroidal Antiinflammatory Drugs,An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007;115:1634-1642.
32. Siobal M. Aerosolized Prostacyclins. Respir Care. 2004;49(6): 640-652.
33.余翠琴.凯时的制剂特点.中国医院药学杂志. 2002;22(11): 691-692.
34. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therpy. N ENGL J MED. 2006, 355(17): 1780-9.
35. Heim SW, Schectman JM, Siadaty MS, et al. D-dimer testing for deep venous thrombosis: a metaanalysis. Clinical Chemistry. 2004, 50(7): 1136-1147.
36. Ombandza-Moussa E, Samama MM, Horellou MH, et al. Potential use of D-dimermeasurement in patients treated with oral anticoagulant for a venous thromboembolic episode. Int Angiol. 2003; 22(4):364-9.
37. Eichinger S, Minar E, Bialonczyk C. et al. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA. 2003; 290:1071-1074.
38. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007; 5: 63-73.
39.靳毅,邢辉,王晓蓓. D-二聚体测定在血栓性疾病诊疗中的临床应用.中华医学杂志. 2007,87(32):2278-2280.
40. G.Reber, H.Bounameaux, A.Peerier and P.de Moerloose. Performances of a new,automated latex assay for the exclusion of venous thromboembolism. Blood Coagulation and Fibrinolysis 2001,12:217-220.
41. Piedad Villla, Fernando Ferrando, Joesp Serra,et al.Quantification of D-dimer using a new fully automated assay: its application for the diagnosis of deep vein thrombosis. Haematologica 2000,85:520-524.
42. Teruko Fukuda, Hidetoshi Kasai, Takeo Kusano, et al. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. Thromb Res2007:120(5):695-701.
43. Robert C. Gosselin, John t. Owings, Joshua Kehoe, et al. Comparison of six D-dimer methods in patients suspected of deep vein thromosis. Blood Coagulation and Fibrinolysis2003,14(6):545-550
44. Haglund U. Gut ischaemia. Gut. 1994;supplement 1:73-76
45. Haglung U, Osterberg J. Local consequences of reperfusion in the gut. In: Piece A, Robert TM. Ischemia-Reperfusion injury. Blackwell Science, Oxford UK. 1999:65-69.
46. Haglund U, Bulkley GB, Granger DN. On the pathophysiology of intestinal ischemic injury. Acta Chir Scand 1987; 153: 321-4.
47. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. Arch Surg. 1970; 101: 478-83.
48. Park PO, Haglund U. Regeneration of small bowel mucosa after intestinal ischemia. Crit Care Med. 1992;20: 135-9.
1. Zhang J, Duan ZQ, Song QB, et al. Acute mesenteric venous thrombosis: a better outcome achieved through improved imaging techniques and a changed policy of clinical management. Eur J Vasc Endovasc Surg. 2004;28(3):329-34.
2. Acosta S, Ogren M, Sternby NH, et al. Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. J Vasc Surg. 2005 Jan;41(1):59-63.
3. Elliot JW. The operative relief of gangrene of intestine due to occlusion of the mesenteric vessels. Ann Surg 1895;21:9-23.
4. Warren S, Eberhard TP. Mesenteric venous thrombosis. Surg Gynecol Obstet 1935;61:102-21.
5. Rhee RY, Gloviczki P.Mesenteric venous thrombosis. Surg Clin North Am. 1997 Apr;77(2):327-38.
6. Boley SJ, Kaleya RN, Brandt LJ. Mesenteric venous thrombosis. Surg Clin North Am 1992;72:183-201.
7. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345(23): 1683-1688
8. Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006; 12(8):1165-74.
9. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531
10. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology. 1982;82:358-72.
11. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1991 to 1984. Surgery 1987; 101: 383-388
12. Harward RS, Green D, Bergan JJ, et al. Mesenteric venous thrombosis. J Vasc Surg. 1989; 9:328-333.
13. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
14. Kispert JF, Kazmers A. Acute intestinal ischemia caused by mesenteric venousthrombosis. Semin Vasc Surg. 1990; 3:157-171
15. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
16. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
17. Amarapurkar DN, Patel ND, Jatania J. Primary mesenteric venous thrombosis: a study from western India. Indian J Gastroenterol. 2007; 26(3):113-7.
18. Narawane NM, Phadke AY, Shah SK, et al. Jejunal stricture complicating acute mesenteric venous thrombosis secondary to protein C deficiency and factor V Leiden gene mutation. Indian J Gastroenterol. 2000;19(2):79-80.
19. Green D, Ganger DR, Blei AT. Protein-C deficiency in splanchnic venous thrombosis. Am J Med. 1987; 82:171.
20. Olson JF, Steuber CP, et al. Functional deficiency of protein C associated with mesenteric venous thrombosis and splenic infarctioin. Am J Pediatr Hematol Oncol.1991; 139(2): 168.
21. De Stefano V, Leone G, et al. Mesenteric vein thrombosis in protein S congenital deficiency. Thromb Res. 1990;57:935.
22. Broekmans AW, Van Rooyen W, et al. Mesenteric vein thrombosis as presenting manifestation of herediatary protein S deficiency. Gastroenterology. 1987;92:240.
23. Maung R, Kelly JK, et al. Mesenteric venous thrombosis due tu antithrombin III deficiency. Arch Pthol Lab Med. 1998;112: 37.
24. Condat B, Pessione F, Denninger MH, et al. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32(3):466-470.
25. Marie I, Levesque H, Le Cam-Duchez V, et al. Mesenteric venous thrombosis revealing both factor II G20212A mutation and hyperhomocysteinemia related to pernicious anemia. Gastroenterology. 2000;118(1):237-8.
26. Hassan HA.Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol. 1999;29(1):90-5.
27. Schneiderman DJ, Cello IP. Intestinal ischemia and infarction associated with oralcontraceptives. West J Med. 1986;77:350
28. Hassan HA, Raufman JP.Mesenteric venous thrombosis. South Med J. 1999;92(6):558-62.
29. Bradbury MS, Kavanagh PV, Chen MY, et al. Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies. J Comput Assist Tomogr. 2002;26:392-404
30. Kumar S, Starr MG, Kamah PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683-1688.
31. Parkeer HH, Bynoe RP, Nottingham JM. Thrombosis of the portal venous system after splenectomy for trauma. J Trauma. 2003;54:193-196
32. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70: 126-132
33. McKinsey JF, Gewertz BL.Acute mesenteric ischemia. Surg Clin North Am. 1997;77(2):307-18.
34. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
35. Clavien PA, Durig M, Harder F. Venous mesenteric infarction: a particular entity. Br J Surg 1988; 75:252-5.
36. Choudhary AM, Grayer D, Nelson A, Roberts I. Mesenteric venous thrombosis. J Clin Gastroenterol 2000; 31:179-82.
37. Hassan HA, Raufman JP, Mesenteric venous thrombosis. South Med J. 1999;92: 558-62.
38. Rhee RY, Gloviczki P, Mendonca CT. Mesenteric venous thrombosis: still a lethal disease in the 1990's. J Vas Surg 1994; 20:688-97.
39. Alam KM, Kayali AE, Mohammed AA, Galul RT. Superior mesenteric venous thrombosis: Riyadh Central Hospital experience. Kuwait Med J 2001; 33:18-21.
40. Rahmouni A, Mathieu D, Golli M, Douek P, Anglade MC, Caillet H,et al. Value of CT and Sonography in conservative management of Acute splenoportal and superior mesenteric venous thrombosis. Gastrointest radiol 1992; 17:135-140.
41. Wilson C, Walker ID, Davidson. Imrie CW. Mesenteric venous thrombosis andantithrombin III deficiency. J Clin Pathol 1987; 40: 906-8.
42. Miller VE, Berland LL. Pulsed Doppler sonography and CT of portal vei thrombosis. Am J Roentgenol. 1985; 145:73-7.
43. Klein HM, Lensing R, Klosterhalfen B, Tons C, Gunther RW. Diagnostic imaging of mesenteric infarction. Radiology 1995; 197:79-82.
44. Jorgensen JE, Hawkins RE, Bredenberg CE. Abdominal vascular catastrophes. Surg Clin North Am 1997; 77:1305-1321.
45. Federle MP, Chun G, Jeffrey RB, Rayor R. Computed tomographic findings in bowel infarction. Am J Roentgenol. 1984; 142:91-5.
46. Kim JY, Hyun HK, Byun JY, Lee JM, Yong BK, Kim IC, et al. Intestinal infarction secondary to mesenteric venous thrombosis: CT-pathologic correlation. J Comput Assist Tomogr. 1993; 17:382-85.
47. Clark RA. Computed tomography of bowel infarction. . J Comput Assist Tomogr. 1987; 11:757-62.
48. Taourel PG, Deneuville M, Pradel JA, et al. Acute mesenteric ischemia: diagnosis with contrast-enhanced CT. Radiology. 1996;199:632-636
49. Bradbury MS, Kavanagh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. RadioGraphics. 2002;22:527-541
50. Kirkpatrick IDC, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. Radiology. 2003;229:91-98.
51. Macari M, Chandarana H, Balthazar E, et al. Intestinal ischemia versus intramural hemorrhage: CT evaluation. AJR. 2003;180:177-184.
52. Kramer CM, Budoff MJ, Fayad ZA, et al. ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. J Am Coll Cardiol. 2007;50:1097-1114.
53. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
54. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886.
55. Ernst CB, Stanley JC. Current therapy in vascular surgery. 4th ed. St. Louis: MosbyInc.2001:693-697.
56. Naitove A, Weissman RE. Primary mesenteric venous thrombosis. Ann Surg. 1965;161:516-523.
57. Robin P, Gruel Y, Lang M, et al. Complete thrombolysis of mesenteric vein occlusion with recombinant tissue-type plasminogen activator. Lancet. 1988;1(2):1391.
58.张健,段志泉,罗英伟等.急性肠系膜上静脉血栓形成的诊治分析.中华普通外科杂志. 2005;20(1): 21-23
59. Bilbao JI, Rodriguez-Cabello J, Longo J, et al. Portal thrombosis percutaneous transhepatic treatment with urokinase-a case report. Gastrointest Radiol. 1989;14:326-328
60. Rivitz SM, Geller SC, Hahn C, et al. Treatment of acute mesenteric venous thrombosis with transjugular intramesenteric urokinase infusion. J Vasc Intervent Radiol. 1995;6:219-223.
61. Poplausky MR, Kaufman JA, Geller SG, et al. Mesenteric venous thrombosis treated with urokinase via the superior mesenteric artery. Gastroenterology. 1996; 110: 1633-1635
62. Bulkley GB, Zuidema GD,Hamilton SR, et al. Intraoperative determination of small intestinal viability following ischemic injury: A prospective controlled trial of two adjuvant methods (Doppler and fluorescein) compared with standard clinical judgment. Ann Surg. 1981;193:628-637
63. Cooperman M, Martin EW, Carey LC. Determination of intestinal viability by Doppler ultrasonography in venous infarction. Ann Surg. 1980;191:57-58.
64. Klempnauer J, Grothues F, Bektas H, et al. Results of portal thrombectomy and splanchnic thrombolysis for the surgical management of acute mesentericoprotal thrombosis. Br J Surg. 1997;84(1):129-132.
65. Langnas AN, Marujo C, Stratta RJ, et al. A selective approach to preexisting portal vein thrombosis in patients undergoing liver transplantation. Am J Surg. 1992;163:132-136.
66. Inahara T. Acute superior mesenteric venous thrombosis treatment by thrombectomy. Ann Surg. 1971;174;:956-961.
67. Kazmers A. Operative management of acute mesenteric ischemia. Ann Vasc Surg. 1998;12:187-197
68. Sehgal M, Haskal ZJ. Use of transjugular intrahepatic portosystemic shunts during lytic therapy of extensive portal splenic and mesenteric venous thrombosis: long-term follow-up. JVIR. 2000;11:61-65
69. Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol. 2005;16:651-661.
70. Kim HS, Patra A, Khan J, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radilo. 2005;16:1685-1691.
71. Safieddine N, Mamazza J, Common A, et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. J Can Chir. 2007;50(1):68-69
72. Haskal ZJ, Edmond J, Brown R. Mesenteric venous thrombosis. N Engl J Med. 2002; 346:1252-1253.
73. Ludwig DJ, Hauptmann E, Rossoff, et al. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg. 1999;30:511-554.
74. Antoch G, Taleb N, Hansen O, et al. Transarterial thrombolysis of portal and mesenteric vein thrombosis: a promising alternative to common therapy. Eur J Endovasc Surg. 2001;21:471-472.
75. Aytekin C, Boyat F, Kurt A, et al. Catheter-directed thrombolysis with transjugular access in portal vein thrombosis secondary to pancreatitis. Eur J Radiol. 2001;39:80-82
76. Ciecarelli O, Goffette P, Laterre PF, et al. Transjugular intrahepatic portosystemic shunt approach and local thrombolysis for treatment of early posttransplant portal vein thrombosis. Transplantation. 2001;72:159-161.
1. CrippaL,Vigano S,Angelo D, et al. The Utility and Cost-Effectivieness of D-dimer Measurements In The Diagnosis of Deep Vein Thrombosis. Haematologica 1997;82:446-451.
2. Reber G, Bounameaux H, Peerier A, et al. Performances of a new,automated latex assay for the exclusion of venous thromboembolism. Blood Coagulation and Fibrinolysis 2001,12:217-220.
3. Villla P, Ferrando F, Serra J,et al.Quantification of D-dimer using a new fully automated assay: its application for the diagnosis of deep vein thrombosis. Haematologica 2000,85:520-524.
4. Fukuda T, Kasai H, Kusano T, et al. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. Thromb Res2007:120(5):695-701.
5. Robert C. Gosselin, John t. Owings, Joshua Kehoe, et al. Comparison of six D-dimer methods in patients suspected of deep vein thromosis. Blood Coagulation and Fibrinolysis2003,14(6):545-550
6. Scarvelis D , Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ.2006,175(9):1087-1092.
7. Yamki T,Noxaki M ,Sakurai H ,et al. Prospective evaluation of a screening protocol to exclude deep vein thrombosis on the basis of a combination of quantitative D -dimer testing and pretest clinical probability score [J].J A M Coll Surg , 2005 ,201(5):701—709.
8. Cogo A, Lensing AW, Koopman MW, et al. Compression ultrasongraphy for diagnostic management of patients with clinically suspected deep vein thrombosis:prospective cohort study. BMJ1998;316:17-20.
9. Goodacre M, Stevenson M, Wailoo A, et al. How should we diagnose suspected deep-vein thrombosis? QJM2006;99:377-388.
10. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Annals of Family Medicine.2007;5(1):63-73.
11. Engelhardt W, Palareti G, Legnani C, et al. Comparative evaluation of D-dimer assays for exclusion of deep venous thrombosis in symptomatic outpatients. Thrombosis Research.2003;112:25-32.
12. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. Journal of Thrombosis and Thrombolysis.2008;25(1):37-44
13. Carrier M , Wells PS , Rodger MA. Excluding pulmonaryembolism at the bedside with low pre-test probability and D-dimer : Safety and clinical utility of 4 met hods to assign pre-test probability[J ] . Thromb Research , 2006 ,117 (4) :469-474.
14. Kearon C. Diagnosis of pulmonary embolism. CMAJ2003;168(2)183-194.
15. Elias A , Cazanave A , Elias M ,et al . Diagnostic management of pulmonary embolism using clinical assessment , plasma D-dimer assay , complete lower limb venous ultrasound and helicalcomputed tomography of pulmonary arteries. A multicent reclinical outcome study[J ] . Thromb Haemost , 2005 ,93 (5) :982-988.
16. Righini M; Aujesky D, Roy PM , et al. Clinical usefulness of D-dimer depending on clinical probability and cutoff value in outpatients with suspected pulmonary embolism. Arch Intern Med 2004; 164: 2483-2487.
17. Kearon C,. Ginsberg JS, Douketis J, et al. An evaluation of D-Dimer in the diagnosis of pulmonary embolism. A randomized trial. Annals of Internal Medicine, 2006,144(11):812-821.
18. Gal GL, Righini M, Roy PM, et al. Value of D-Dimer Testing for the Exclusion of Pulmonary Embolism in Patients With Previous Venous Thromboembolism. Original Investigation. 2006;166:176-180.
19. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation, 1992,86:195.
20. Toss H, Lindahl B, Siegbahn A, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation1997;96:4204-4210.
21. Danesh J , Whincup P , Walker M , et al. Fibrin D-dimer and coronary heart disease : prospective study and meta-analysis. Circulation , 2001 ,103 :2323 - 2327.
22. Stott DJ, Spilg E, Campbell AM, Rumley A, et al. Haemostasis in ischaemic stroke and vasvular dementia.Blood Coagulation and Fibrinolysis 2001, 12: 651-657.
23. Hoffmeister HM, Jur M,Wemdel HP , et al . Alterations of coagulation and fibrinolytic and kallikreinkinin systems in the acute and postacute phase in patients with unstable angina pectoris[J ] . Circulation , 1995 ,91 :2520-2527.
24. Ageno W, Finazzi S, Steidl L, et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes [ J] .Arch Intern Med, 2002, 162: 2589- 2593.
25. Koch HJ, Horn M, Bogdahn U, et al. The relationship between plasma D-dimer concentrations and acute ischemic stroke subtypes. Journal of Stroke and Cerebrovascular Diseases,2005;14(2)75-79.
26. Fujii Y,Takeuchi S , Harada A , et al . Hemostatic activation in spontaneous intracerebral hemorrhage[J ] . Stroke ,2001 ,32 :8832890.
27. Koch HJ, Uyanik G, Bogdahn U, et al. Relaion between laterality and immune response after acute cerebral ischemia. Neuroimmuomodulation2006;13:8-12.
28. Dinisio M, Rutjes AWS, Buller H. Combined use of clinical pretest probability and D-dimer test in cancer patients with clinically suspected deep venous thrombosis. Journal of Thrombosis and Haemostasis,2005;4:52-57.
29. Altiay G, Ciftci A, Demirt M. et al. High plasma d-dimer level is associated with decreased survival in patients with lung cancer. Clinical Oncology2007;19:494-498.
30. Kim HK, Lee KR, Yang JH, et al. Plasma levels of d-dimer and soluble fibrinpolymer in patients with hepatocellular carcinoma: a possible predictor of tumor thrombosis. Thrombosis research.2003,109:125-129.
31. Blackwell K, Haroon Z, Braadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. Journal of Clinical Oncology2000;18(3):600-608.
32. Kruskal JB , Robson SC , Franks JJ , et al. Elevated fibrin related and fibrinogen related antigens in patients with liver diseases. Hepatology, 1992 ,16 :920-923.
33. Spadaro A, Tortorella V, Morace C, et al. High circulating d-dimer are associated with ascites and hepatocellular carcinoma in liver cirrhosis. World J Gastroenterol 2008;14(10):1549-1552.
34. Primignani M, Dell’Era A,et al. High-d-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Digestive and Liver Disease, 2008:1238
35. Nijkeuter M, Ginsberg JS and Huisman MV. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. Journal of thrombosis and haemostasis 2006;4:496-500.
36. Kline JA, Williams GW, and Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Hemostasis and Thrombosis2005;51:825-829.
37. Eldor A. The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. European Journal of Obstetrics and Gynecology and Reproductive Biology 2002;104:3-13.
38. Ian A.Greer.Venous thromboembolism and anticoagulant therapy in pregnancy. Gender Medicine.2005;2supplement A:S10-S17.
39. Ian A.Greer. Prevention of venous thromboembolism in pregnancy. Best Practice and Research Clinical Haematology.2003;16(2):261-278.
40. Ohlmann P, Faure A. Diagnostic and prognostic value of circulating D-Dimers in patients with acute aortic dissection. Crit Care Med,2006,34, (5):1358-1364.
2. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1911 to 1984. Surgery 1987; 101: 383-388.
3. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
4. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
5. Zhang J, Duan ZQ, Song QB, et al. Acute mesenteric venous thrombosis: a better outcome achieved through improved imaging techniques and a changed policy of clinical management. Eur J Vasc Endovasc Surg. 2004;28(3):329-34.
6. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg. 2001; 34:673-9.
7. Salamah SMA, Mirza SM. Acute mesenteric venous thrombosis: management controversies. JK-Practitioner. 2004; 11(4):242-247
8. Grieshop RJ, Dalsing MC, Cikrit DF, Lalka SG, Sawchuk A. Acute mesenteric venous thrombosis. Revisited in a time of diagnosis clarity. Am Surg 1991;57:573-7.
9. Harward TR, Green D, Bergan JJ, Rizzo RJ, Yao JST. Mesenteric venous thrombosis. J Vasc Surg 1989;9:328-33.
10. Rhee RY, Gloviczki P, Mendonca CT, Petterson TM, Serry RD, Sarr MG, et al. Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg 1994;20:688-97.
11. Klempnauer J, Grothues F, Bektas H, Pichlmayr R. Results of portal thrombectomy and splanchnic thrombolysis for the surgical management of acute mesentericoportal thrombosis. Br J Surg 1997;84:129-32.
12. Levy PJ, Krausz MM, Manny J. Acute mesenteric ischemia: improved results—a retrospective analysis of ninety-two patients. Surgery 1990;107:372-80.
13. Inderbitzi R, Wagner HE, Seiler C, Stirnemann P, Gertsch P. Acute mesenteric ischemia. Eur J Surg 1992;158:123-6.
14. Haglund U. Gut ischemia. Gut 1994;35(1 Suppl):S73-6.
15. Levi M, D?rffle-Melly J, Johnson GJ, et al. Usefulness and limitations of animal models of venous thrombosis. Thromb Haemost. 2001; 86(5):1331-3.
16. Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006; 12(8): 1165-1174
17. Elliot JW. The operative relief of gangrene of intestine due to occlusion of the mesenteric vessels. Ann Surg 1895;21:9-23.
18. Warren S, Eberhard TP. Mesenteric venous thrombosis. Surg Gynecol Obstet 1935;61:102-21.
19. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology. 1982;82:358-72.
20. Rhee RY, Gloviczki P.Mesenteric venous thrombosis. Surg Clin North Am. 1997 Apr;77(2):327-38.
21. Boley SJ, Kaleya RN, Brandt LJ. Mesenteric venous thrombosis. Surg Clin North Am 1992;72:183-201.
22. Acosta S, Ogren M, Sternby NH, et al. Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. J Vasc Surg. 2005 Jan;41(1):59-63.
23. Kramer CM, Budoff MJ, Fayad ZA, et al. ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. J Am Coll Cardiol. 2007;50:1097-1114.
24. Taourel PG, Deneuville M, Pradel JA, et al. Acute mesenteric ischemia: diagnosis with contrast-enhanced CT. Radiology. 1996;199:632-636.
25. Bradbury MS, Kavanagh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. RadioGraphics. 2002;22:527-541.
26. Kirkpatrick IDC, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. Radiology. 2003;229:91-98.
27. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004:1078-1090.
28. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1920-1940.
29. Kearon C. Natural History of Venous Thromboembolism. Circulation. 2003; 107: I-22-I-30.
30. Tovey C, Wyatt S. Diagnosis, investigation, and management of deep vein thrombosis. BMJ. 2003; 326: 1180-1184.
31. Anderson FA, Spencer FA. Risk Factors for Venous Thromboembolism. Criculation. 2003; 107: I-9-I-16.
32. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107: I-4-I-8.
33. Segal JB, Streiff MB, Hofman LV, et al. Management of venous thromboembolism a systematic review for a practice guideline. Ann Intern Med. 2007; 146: 211-222.
34. Hirsh J, O’Donnell M, Eikelboom JW. Beyond Unfractionated Heparin and Warfarin Current and Future Advances. Criculation. 2007; 116: 552-560.
35. Valji K, Bookstein JJ. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Radiology. 1993;186(3):873-6.
36. Aruva MR, Daviau J, Sharma SS, et al. Imaging thromboembolism with fibrin-avid 99mTc-peptide: evaluation in swine. J Nucl Med. 2006;47(1):155-62.
37. Wojewódzka-Zelezniakowicz M, Chabielska E, Mogielnicki A, et al. Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats. J Physiol Pharmacol. 2006;57(2):231-45.
38. Rosenfield AT, Zeman RK, Cronan JJ, et al. Ultrasound in experimental and clinical renal vein thrombosis. Radiology. 1980;137(3):735-41.
39. Korninger C, Matsuo O, Suy R, et al. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest. 1982 ;69(3):573-80.
40. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect ofmolecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest. 1983;71(2):368-76.
41. Rich NM, Hobson RW, Collins GJ, et al. The effect of acute popliteal venous interruption. Ann Surg. 1976;183(4):365-8.
42. Biemond BJ, Levi M, Coronel R, et al. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1995;91(4):1175-81.
43. Yokota K, Yamashita A, Oda M. Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis. Jpn J Pharmacol. 1995;68(2):201-6.
44. Minnema MC, Friederich PW, Levi M, et al.Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest. 1998 ;101(1):10-4.
45. Biemond BJ, Friederich PW, Koschinsky ML, et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation. 1997;96(5):1612-5.
46. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood. 1997;89(4):1270-8.
47. Biemond BJ, Friederich PW, Levi M, et al. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation. 1996 1;93(1):153-60.
48. Nakase H, Heimann A, Kempski O. Alterations of regional cerebral blood flow and oxygen saturation in a rat sinus-vein thrombosis model. Stroke. 1996;27(4):720-7; discussion 728.
49. Hennan JK, Hong TT, Shergill AK, et al. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther. 2002;301(3):1151-6.
50. Kang SG, Chung H, Hyon JY. Experimental preretinal neovascularization by laser-induced thrombosis in albino rats. Korean J Ophthalmol. 1999 Dec;13(2):65-70.
51. Schaller B, Graf R, Wienhard K, et al. A new animal model of cerebral venousinfarction: ligation of the posterior part of the superior sagittal sinus in the cat. Swiss Med Wkly. 2003 ;133(29-30):412-8.
52. Di Domenico S, Bovio G, Gelli M, et al. Cavo-portal transposition in rat: a new simple model. BMC Surg. 2007;7:18.
53. Chauhan AK, Kisucka J, Lamb CB, et al. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109(6):2424-9.
54. Narawane NM, Phadke AY, Shah SK, et al. Jejunal stricture complicating acute mesenteric venous thrombosis secondary to protein C deficiency and factor V Leiden gene mutation. Indian J Gastroenterol. 2000;19(2):79-80.
55. Green D, Ganger DR, Blei AT. Protein-C deficiency in splanchnic venous thrombosis. Am J Med. 1987; 82:171.
56. Olson JF, Steuber CP, et al. Functional deficiency of protein C associated with mesenteric venous thrombosis and splenic infarctioin. Am J Pediatr Hematol Oncol.1991; 139(2): 168.
57. De Stefano V, Leone G, et al. Mesenteric vein thrombosis in protein S congenital deficiency. Thromb Res. 1990;57:935.
58. Broekmans AW, Van Rooyen W, et al. Mesenteric vein thrombosis as presenting manifestation of herediatary protein S deficiency. Gastroenterology. 1987;92:240.
59. Maung R, Kelly JK, et al. Mesenteric venous thrombosis due tu antithrombin III deficiency. Arch Pthol Lab Med. 1998;112: 37.
60. Condat B, Pessione F, Denninger MH, et al. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32(3):466-470.
61. Marie I, Levesque H, Le Cam-Duchez V, et al. Mesenteric venous thrombosis revealing both factor II G20212A mutation and hyperhomocysteinemia related to pernicious anemia. Gastroenterology. 2000;118(1):237-8.
62. Hassan HA.Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol. 1999;29(1):90-5.
63. Schneiderman DJ, Cello IP. Intestinal ischemia and infarction associated with oralcontraceptives. West J Med. 1986;77:350
64. Hassan HA, Raufman JP.Mesenteric venous thrombosis. South Med J. 1999;92 (6):558-62.
65. Bradbury MS, Kavanagh PV, Chen MY, et al. Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies. J Comput Assist Tomogr. 2002;26:392-404
66. Parkeer HH, Bynoe RP, Nottingham JM. Thrombosis of the portal venous system after splenectomy for trauma. J Trauma. 2003;54:193-196
67. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70: 126-132
68. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therpy. N ENGL J MED. 2006, 355(17): 1780-9.
69. Heim SW, Schectman JM, Siadaty MS, et al. D-dimer testing for deep venous thrombosis: a metaanalysis. Clinical Chemistry. 2004, 50(7): 1136-1147.
70. Ombandza-Moussa E, Samama MM, Horellou MH, et al. Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode. Int Angiol. 2003; 22(4):364-9.
71. Eichinger S, Minar E, Bialonczyk C. et al. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA. 2003; 290:1071-1074.
72. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007; 5: 63-73.
73.靳毅,邢辉,王晓蓓. D-二聚体测定在血栓性疾病诊疗中的临床应用.中华医学杂志. 2007,87(32):2278-2280.
74.王克俊,荆蕊平,耿海燕等. D-二聚体定量测定在AMI溶栓治疗检测中的应用.放射免疫学杂志. 2007,20(1): 30-31.
75.丁向民,诸林海,张喜成等. D-二聚体在早期诊断急性肠系膜缺血的价值.中国现代普通外科进展. 2006, 9(6): 349-351
76.王利新,景在平,包俊敏等.急性深静脉血栓治疗前后血清D-二聚体的变化.外科理论与实践. 2005, 10(1): 80-82
77. G.Reber, H.Bounameaux, A.Peerier and P.de Moerloose. Performances of a new,automated latex assay for the exclusion of venous thromboembolism. Blood Coagulation and Fibrinolysis 2001,12:217-220.
78. Piedad Villla, Fernando Ferrando, Joesp Serra,et al.Quantification of D-dimer using a new fully automated assay: its application for the diagnosis of deep vein thrombosis. Haematologica 2000,85:520-524.
79. Teruko Fukuda, Hidetoshi Kasai, Takeo Kusano, et al. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. Thromb Res2007:120(5):695-701.
80. Robert C. Gosselin, John t. Owings, Joshua Kehoe, et al. Comparison of six D-dimer methods in patients suspected of deep vein thromosis. Blood Coagulation and Fibrinolysis2003,14(6):545-550
81.王振义,李家增,阮长耿等主编.血栓与止血:基础与临床.第三版.上海:上海科学技术出版社. 2004: 81-116.
1. Kumar S, Starr MG, Kamah PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683-1688.
2. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1991 to 1984. Surgery 1987; 101: 383-388.
3. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
4. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
5. Zhang J, Duan ZQ, Song QB, et al. Acute mesenteric venous thrombosis: a better outcome achieved through improved imaging techniques and a changed policy of clinical management. Eur J Vasc Endovasc Surg. 2004;28(3):329-34.
6. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
7. Rhee RY, Gloviczki P, Mendonca CT, et al. Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg 1994;20:688-97.
8. Ludwig DJ, Hauptmann E, Rossoff, et al. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg. 1999;30:511-554.
9. Antoch G, Taleb N, Hansen O, et al. Transarterial thrombolysis of portal and mesenteric vein thrombosis: a promising alternative to common therapy. Eur J Endovasc Surg. 2001;21:471-472.
10. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
11. Ludwig DJ, Hauptmann E, Rossoff, et al. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg. 1999;30:511-554.
12. Antoch G, Taleb N, Hansen O, et al. Transarterial thrombolysis of portal and mesenteric vein thrombosis: a promising alternative to common therapy. Eur J Endovasc Surg. 2001;21:471-472.
13. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
14. Salamah SMA, Mirza SM. Acute mesenteric venous thrombosis: management controversies. JK-Practitioner. 2004; 11(4):242-247
15. Kr?ger K, Buss C, Rudofsky G. Retrospective analysis of rt-PA thrombolysis combined with PGE1 in patients with peripheral arterial occlusions. Angiology. 2000; 51(5):377-84.
16. Valji K, Bookstein JJ. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Radiology. 1993; 186: 873-876.
17. Elliot JW. The operative relief of gangrene of intestine due to occlusion of the mesenteric vessels. Ann Surg 1895;21:9-23.
18. Warren S, Eberhard TP. Mesenteric venous thrombosis. Surg Gynecol Obstet 1935;61:102-21.
19. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology. 1982;82:358-72.
20. Rhee RY, Gloviczki P.Mesenteric venous thrombosis. Surg Clin North Am. 1997 Apr;77(2):327-38.
21. Boley SJ, Kaleya RN, Brandt LJ. Mesenteric venous thrombosis. Surg Clin North Am 1992;72:183-201.
22. Ernst CB, Stanley JC. Current therapy in vascular surgery. 4th ed. St. Louis: Mosby Inc.2001:693-697.
23. Naitove A, Weissman RE. Primary mesenteric venous thrombosis. Ann Surg. 1965;161:516-523.
24. Robin P, Gruel Y, Lang M, et al. Complete thrombosis of mesenteric vein occlusion with recombinant tissue-type plasminogen activator. Lancet. 1988;1(2):1391.
25.张健,段志泉,罗英伟等.急性肠系膜上静脉血栓形成的诊治分析.中华普通外科杂志. 2005;20(1): 21-23
26. Bilbao JI, Rodriguez-Cabello J, Longo J, et al. Portal thrombosis percutaneous transhepatic treatment with urokinase-a case report. Gastrointest Radiol. 1989;14:326-328
27. Rivitz SM, Geller SC, Hahn C, et al. Treatment of acute mesenteric venous thrombosiswith transjugular intramesenteric urokinase infusion. J Vasc Intervent Radiol. 1995;6:219-223.
28. Poplausky MR, Kaufman JA, Geller SG, et al. Mesenteric venous thrombosis treated with urokinase via the superior mesenteric artery. Gastroenterology. 1996; 110: 1633-1635
29. Choudhary AM, Grayer D, Nelson A, Roberts I. Mesenteric venous thrombosis. J Clin Gastroenterol 2000; 31:179-82.
30. Alam KM, Kayali AE, Mohammed AA, Galul RT. Superior mesenteric venous thrombosis: Riyadh Central Hospital experience. Kuwait Med J 2001; 33:18-21.
31. Ciecarelli O, Goffette P, Laterre PF, et al. Transjugular intrahepatic portosystemic shunt approach and local thrombolysis for treatment of early posttransplant portal vein thrombosis. Transplantation. 2001;72:159-161.
32. Smalling RW, Feld S, Ramanna N, et al. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation. 1995,15;92(4):935-43.
33. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophsiology of vascular disorders. Blood. 1998; 91(10): 3527-3561.
34. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved Issues in the Role of Cyclooxygenase-2 in Normal Physiologic Processes and Disease. Arch Intern Med. 2000;160: 913-920.
35. Hashiguchi M. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi 2004 124: 321-332.
36. Ozaki Masayuki, Ogata Masanori, Yokoyama Toru, et al. Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. Can J Anesth. 2005;52(2): 143-147.
37. Smalling RW, Feld S, Ramanna N, et al. Use of Nonsteroidal Antiinflammatory Drugs,An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007;115:1634-1642.
38. Vaughan DE, Plavin SR, Schafer AI, et al. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood. 1989 Apr;73(5):1213-7..
39. Terres W, Beythien C, Kupper W, et al. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis. Circulation. 1989; 79(6):1309-14.
40. Kerins DM, Shuh M, Kunitada S, et al. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. J Pharmacol Exp Ther. 1991; 257(1):487-92..
41. Coffman TM, Spurney RF, Mannon RB, et al. Thromboxane A2 modulates the fibrinolytic system in glomerular mesangial cells. Am J Physiol Renal Physiol. 1998; 275: 262-269.
42.李忠诚.尿激酶和凯时联合溶解深静脉血栓的临床研究.中国综合临床. 2002;1:36-38.
43.孙英信,时德,向志等.急性下肢深静脉血栓形成148例的治疗.第四军医大学学报. 2002; 5.
44.余翠琴.凯时的制剂特点.中国医院药学杂志. 2002;22(11): 691-692.
45. Heim SW, Schectman JM, Siadaty MS, et al. D-dimer testing for deep venous thrombosis: a metaanalysis. Clinical Chemistry. 2004, 50(7): 1136-1147.
46. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007; 5: 63-73.
47. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. Journal of Thrombosis and Thrombolysis.2008;25(1):37-44
48. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therpy. N ENGL J MED. 2006, 355(17): 1780-9.
49. Ombandza-Moussa E, Samama MM, Horellou MH, et al. Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode. Int Angiol. 2003; 22(4):364-9.
50. Eichinger S, Minar E, Bialonczyk C. et al. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA. 2003; 290:1071-1074.
51.靳毅,邢辉,王晓蓓. D-二聚体测定在血栓性疾病诊疗中的临床应用.中华医学杂志. 2007,87(32):2278-2280.
52.王克俊,荆蕊平,耿海燕等. D-二聚体定量测定在AMI溶栓治疗检测中的应用.放射免疫学杂志. 2007,20(1): 30-31.
53.丁向民,诸林海,张喜成等. D-二聚体在早期诊断急性肠系膜缺血的价值.中国现代普通外科进展. 2006, 9(6): 349-351
54.王利新,景在平,包俊敏等.急性深静脉血栓治疗前后血清D-二聚体的变化.外科理论与实践. 2005, 10(1): 80-82
55.王振义,李家增,阮长耿等主编.血栓与止血:基础与临床.第三版.上海:上海科学技术出版社. 2004: 3-154.
56. Haglund U. Gut ischaemia. Gut. 1994;supplement 1:73-76
57. Haglung U, Osterberg J. Local consequences of reperfusion in the gut. In: Piece A, Robert TM. Ischemia-Reperfusion injury. Blackwell Science, Oxford UK. 1999:65-69.
58. Haglund U, Bulkley GB, Granger DN. On the pathophysiology of intestinal ischemic injury. Acta Chir Scand 1987; 153: 321-4.
59. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. Arch Surg. 1970; 101: 478-83.
60. Park PO, Haglund U. Regeneration of small bowel mucosa after intestinal ischemia. Crit Care Med. 1992;20: 135-9.
61. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost. 2005 Apr;93(4):627-30.
62. Banerjee A, Chisti Y, Banerjee UC. Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv. 2004 Feb;22(4):287-307.
63. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 184-195.
64. White RA, Hollier LH. Vascular Surgery: Basic Science and Clinical Correlations. 2nd ed. Malden: Blackwell Publishing, 2005: 454-467.
1. Kumar S, Starr MG, Kamah PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683-1688.
2. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1991 to 1984. Surgery 1987; 101: 383-388.
3. Rhee RY, Gloviczki P, Mendonca CT. Mesenteric venous thrombosis: still a lethal disease in the 1990's. J Vas Surg 1994; 20:688-97.
4. Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006; 12(8):1165-74.
5.王玉琦,叶建荣主编.血管外科治疗学.上海:上海科学技术出版社. 2003: 1~14.
6. Banerjee A, Chisti Y, Banerjee UC. Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv. 2004 Feb;22(4):287-307.
7. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication? Thromb Haemost 2001;86:499-508
8. Sze DY, O'Sullivan GJ, Johnson DL,et al. Mesenteric and portal venous thrombosis treated by transjugular mechanical thrombolysis. AJR Am J Roentgenol. 2000; 175(3):732-4.
9. Kim HS, Patra A, Khan J, et al. Transhepatic Catheter-directed Thrombectomy and Thrombolysis of Acute Superior Mesenteric Venous Thrombosis. J Vasc Interv Radiol.2005; 16:1685-1691
10. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
11. Guglielmi A, Fior F, Halmos O, et al. Transhepatic fibrinolysis of mesenteric and portal vein thrombosis in a patient with ulcerative colitis: a case report. World J Gastroenterol.2005; 11(13):2035-8.
12. Kaplan JL, Weintraub SL, Hunt JP,et al. Treatment of superior mesenteric and portal vein thrombosis with direct thrombolytic infusion via an operatively placed mesenteric catheter. Am Surg. 2004; 70(7):600-4.
13. Lopera JE, Correa G, Brazzini A, et al. Percutaneous transhepatic treatment of symptomatic mesenteric venous thrombosis. J Vasc Surg. 2002; 36(5):1058-61.
14. Kim HS, Patra A, Khan J, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radiol. 2005; 16(12):1685-91.
15. Kr?ger K, Buss C, Rudofsky G. Retrospective analysis of rt-PA thrombolysis combined with PGE1 in patients with peripheral arterial occlusions. Angiology. 2000; 51(5):377-84.
16. Valji K, Bookstein JJ. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Radiology. 1993; 186: 873-876.
17. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
18. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
19. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
20.张健,王玉波,张强,等.急性肠系膜静脉血栓形成的非手术治疗.中国实用外科杂志. 2003,23(4): 220-221
21.张健,段志泉,罗英伟,等.急性肠系膜上静脉血栓形成的诊治分析.中华普通外科杂志. 2005,20(1): 21-23
22.王振义,李家增,阮长耿等主编.血栓与止血:基础与临床.第三版.上海:上海科学技术出版社. 2004: 809-824
23. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 184-195
24. White RA, Hollier LH. Vascular Surgery: Basic Science and Clinical Correlations. 2nd ed. Malden: Blackwell Publishing, 2005: 454-467
25. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost. 2005 Apr;93(4):627-30.
26. Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost. 1995 Jul;74(1):387-90.
27. Alpert JS. Importance of the pharmacological profile of thrombolytic agents in clinical practice. Am J Cardiol. 1991 Dec 5;68(16):3E-7E. Review.
28. Smalling RW, Feld S, Ramanna N, et al. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation. 1995,15;92(4):935-43.
29. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi. 2004;124(6): 321-332
30. Ozaki Masayuki, Ogata Masanori, Yokoyama Toru, et al. Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. Can J Anesth. 2005;52(2): 143-147.
31. Smalling RW, Feld S, Ramanna N, et al. Use of Nonsteroidal Antiinflammatory Drugs,An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007;115:1634-1642.
32. Siobal M. Aerosolized Prostacyclins. Respir Care. 2004;49(6): 640-652.
33.余翠琴.凯时的制剂特点.中国医院药学杂志. 2002;22(11): 691-692.
34. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therpy. N ENGL J MED. 2006, 355(17): 1780-9.
35. Heim SW, Schectman JM, Siadaty MS, et al. D-dimer testing for deep venous thrombosis: a metaanalysis. Clinical Chemistry. 2004, 50(7): 1136-1147.
36. Ombandza-Moussa E, Samama MM, Horellou MH, et al. Potential use of D-dimermeasurement in patients treated with oral anticoagulant for a venous thromboembolic episode. Int Angiol. 2003; 22(4):364-9.
37. Eichinger S, Minar E, Bialonczyk C. et al. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA. 2003; 290:1071-1074.
38. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007; 5: 63-73.
39.靳毅,邢辉,王晓蓓. D-二聚体测定在血栓性疾病诊疗中的临床应用.中华医学杂志. 2007,87(32):2278-2280.
40. G.Reber, H.Bounameaux, A.Peerier and P.de Moerloose. Performances of a new,automated latex assay for the exclusion of venous thromboembolism. Blood Coagulation and Fibrinolysis 2001,12:217-220.
41. Piedad Villla, Fernando Ferrando, Joesp Serra,et al.Quantification of D-dimer using a new fully automated assay: its application for the diagnosis of deep vein thrombosis. Haematologica 2000,85:520-524.
42. Teruko Fukuda, Hidetoshi Kasai, Takeo Kusano, et al. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. Thromb Res2007:120(5):695-701.
43. Robert C. Gosselin, John t. Owings, Joshua Kehoe, et al. Comparison of six D-dimer methods in patients suspected of deep vein thromosis. Blood Coagulation and Fibrinolysis2003,14(6):545-550
44. Haglund U. Gut ischaemia. Gut. 1994;supplement 1:73-76
45. Haglung U, Osterberg J. Local consequences of reperfusion in the gut. In: Piece A, Robert TM. Ischemia-Reperfusion injury. Blackwell Science, Oxford UK. 1999:65-69.
46. Haglund U, Bulkley GB, Granger DN. On the pathophysiology of intestinal ischemic injury. Acta Chir Scand 1987; 153: 321-4.
47. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. Arch Surg. 1970; 101: 478-83.
48. Park PO, Haglund U. Regeneration of small bowel mucosa after intestinal ischemia. Crit Care Med. 1992;20: 135-9.
1. Zhang J, Duan ZQ, Song QB, et al. Acute mesenteric venous thrombosis: a better outcome achieved through improved imaging techniques and a changed policy of clinical management. Eur J Vasc Endovasc Surg. 2004;28(3):329-34.
2. Acosta S, Ogren M, Sternby NH, et al. Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. J Vasc Surg. 2005 Jan;41(1):59-63.
3. Elliot JW. The operative relief of gangrene of intestine due to occlusion of the mesenteric vessels. Ann Surg 1895;21:9-23.
4. Warren S, Eberhard TP. Mesenteric venous thrombosis. Surg Gynecol Obstet 1935;61:102-21.
5. Rhee RY, Gloviczki P.Mesenteric venous thrombosis. Surg Clin North Am. 1997 Apr;77(2):327-38.
6. Boley SJ, Kaleya RN, Brandt LJ. Mesenteric venous thrombosis. Surg Clin North Am 1992;72:183-201.
7. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345(23): 1683-1688
8. Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006; 12(8):1165-74.
9. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531
10. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology. 1982;82:358-72.
11. Abdu RA, Zakhour BJ,Dallis DJ. Mesenteric venous thrombosis 1991 to 1984. Surgery 1987; 101: 383-388
12. Harward RS, Green D, Bergan JJ, et al. Mesenteric venous thrombosis. J Vasc Surg. 1989; 9:328-333.
13. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
14. Kispert JF, Kazmers A. Acute intestinal ischemia caused by mesenteric venousthrombosis. Semin Vasc Surg. 1990; 3:157-171
15. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886
16. Safieddine N, Mamazza J, Common A,et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. Can J Surg. 2007; 50(1):68-9.
17. Amarapurkar DN, Patel ND, Jatania J. Primary mesenteric venous thrombosis: a study from western India. Indian J Gastroenterol. 2007; 26(3):113-7.
18. Narawane NM, Phadke AY, Shah SK, et al. Jejunal stricture complicating acute mesenteric venous thrombosis secondary to protein C deficiency and factor V Leiden gene mutation. Indian J Gastroenterol. 2000;19(2):79-80.
19. Green D, Ganger DR, Blei AT. Protein-C deficiency in splanchnic venous thrombosis. Am J Med. 1987; 82:171.
20. Olson JF, Steuber CP, et al. Functional deficiency of protein C associated with mesenteric venous thrombosis and splenic infarctioin. Am J Pediatr Hematol Oncol.1991; 139(2): 168.
21. De Stefano V, Leone G, et al. Mesenteric vein thrombosis in protein S congenital deficiency. Thromb Res. 1990;57:935.
22. Broekmans AW, Van Rooyen W, et al. Mesenteric vein thrombosis as presenting manifestation of herediatary protein S deficiency. Gastroenterology. 1987;92:240.
23. Maung R, Kelly JK, et al. Mesenteric venous thrombosis due tu antithrombin III deficiency. Arch Pthol Lab Med. 1998;112: 37.
24. Condat B, Pessione F, Denninger MH, et al. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32(3):466-470.
25. Marie I, Levesque H, Le Cam-Duchez V, et al. Mesenteric venous thrombosis revealing both factor II G20212A mutation and hyperhomocysteinemia related to pernicious anemia. Gastroenterology. 2000;118(1):237-8.
26. Hassan HA.Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol. 1999;29(1):90-5.
27. Schneiderman DJ, Cello IP. Intestinal ischemia and infarction associated with oralcontraceptives. West J Med. 1986;77:350
28. Hassan HA, Raufman JP.Mesenteric venous thrombosis. South Med J. 1999;92(6):558-62.
29. Bradbury MS, Kavanagh PV, Chen MY, et al. Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies. J Comput Assist Tomogr. 2002;26:392-404
30. Kumar S, Starr MG, Kamah PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345:1683-1688.
31. Parkeer HH, Bynoe RP, Nottingham JM. Thrombosis of the portal venous system after splenectomy for trauma. J Trauma. 2003;54:193-196
32. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70: 126-132
33. McKinsey JF, Gewertz BL.Acute mesenteric ischemia. Surg Clin North Am. 1997;77(2):307-18.
34. Brunaud L, Antunes L, Adler SC, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vas Surg 2001; 34:673-9.
35. Clavien PA, Durig M, Harder F. Venous mesenteric infarction: a particular entity. Br J Surg 1988; 75:252-5.
36. Choudhary AM, Grayer D, Nelson A, Roberts I. Mesenteric venous thrombosis. J Clin Gastroenterol 2000; 31:179-82.
37. Hassan HA, Raufman JP, Mesenteric venous thrombosis. South Med J. 1999;92: 558-62.
38. Rhee RY, Gloviczki P, Mendonca CT. Mesenteric venous thrombosis: still a lethal disease in the 1990's. J Vas Surg 1994; 20:688-97.
39. Alam KM, Kayali AE, Mohammed AA, Galul RT. Superior mesenteric venous thrombosis: Riyadh Central Hospital experience. Kuwait Med J 2001; 33:18-21.
40. Rahmouni A, Mathieu D, Golli M, Douek P, Anglade MC, Caillet H,et al. Value of CT and Sonography in conservative management of Acute splenoportal and superior mesenteric venous thrombosis. Gastrointest radiol 1992; 17:135-140.
41. Wilson C, Walker ID, Davidson. Imrie CW. Mesenteric venous thrombosis andantithrombin III deficiency. J Clin Pathol 1987; 40: 906-8.
42. Miller VE, Berland LL. Pulsed Doppler sonography and CT of portal vei thrombosis. Am J Roentgenol. 1985; 145:73-7.
43. Klein HM, Lensing R, Klosterhalfen B, Tons C, Gunther RW. Diagnostic imaging of mesenteric infarction. Radiology 1995; 197:79-82.
44. Jorgensen JE, Hawkins RE, Bredenberg CE. Abdominal vascular catastrophes. Surg Clin North Am 1997; 77:1305-1321.
45. Federle MP, Chun G, Jeffrey RB, Rayor R. Computed tomographic findings in bowel infarction. Am J Roentgenol. 1984; 142:91-5.
46. Kim JY, Hyun HK, Byun JY, Lee JM, Yong BK, Kim IC, et al. Intestinal infarction secondary to mesenteric venous thrombosis: CT-pathologic correlation. J Comput Assist Tomogr. 1993; 17:382-85.
47. Clark RA. Computed tomography of bowel infarction. . J Comput Assist Tomogr. 1987; 11:757-62.
48. Taourel PG, Deneuville M, Pradel JA, et al. Acute mesenteric ischemia: diagnosis with contrast-enhanced CT. Radiology. 1996;199:632-636
49. Bradbury MS, Kavanagh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. RadioGraphics. 2002;22:527-541
50. Kirkpatrick IDC, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. Radiology. 2003;229:91-98.
51. Macari M, Chandarana H, Balthazar E, et al. Intestinal ischemia versus intramural hemorrhage: CT evaluation. AJR. 2003;180:177-184.
52. Kramer CM, Budoff MJ, Fayad ZA, et al. ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. J Am Coll Cardiol. 2007;50:1097-1114.
53. Rutherford RB. Vascular Surgery. 5th ed. Phliadelphia: WB Saunders Company, 2000:1524-1531.
54. Ascher E. Haimovici’s Vascular Surgery. 5th ed. Malden: Blackwell Publishing, 2004: 875-886.
55. Ernst CB, Stanley JC. Current therapy in vascular surgery. 4th ed. St. Louis: MosbyInc.2001:693-697.
56. Naitove A, Weissman RE. Primary mesenteric venous thrombosis. Ann Surg. 1965;161:516-523.
57. Robin P, Gruel Y, Lang M, et al. Complete thrombolysis of mesenteric vein occlusion with recombinant tissue-type plasminogen activator. Lancet. 1988;1(2):1391.
58.张健,段志泉,罗英伟等.急性肠系膜上静脉血栓形成的诊治分析.中华普通外科杂志. 2005;20(1): 21-23
59. Bilbao JI, Rodriguez-Cabello J, Longo J, et al. Portal thrombosis percutaneous transhepatic treatment with urokinase-a case report. Gastrointest Radiol. 1989;14:326-328
60. Rivitz SM, Geller SC, Hahn C, et al. Treatment of acute mesenteric venous thrombosis with transjugular intramesenteric urokinase infusion. J Vasc Intervent Radiol. 1995;6:219-223.
61. Poplausky MR, Kaufman JA, Geller SG, et al. Mesenteric venous thrombosis treated with urokinase via the superior mesenteric artery. Gastroenterology. 1996; 110: 1633-1635
62. Bulkley GB, Zuidema GD,Hamilton SR, et al. Intraoperative determination of small intestinal viability following ischemic injury: A prospective controlled trial of two adjuvant methods (Doppler and fluorescein) compared with standard clinical judgment. Ann Surg. 1981;193:628-637
63. Cooperman M, Martin EW, Carey LC. Determination of intestinal viability by Doppler ultrasonography in venous infarction. Ann Surg. 1980;191:57-58.
64. Klempnauer J, Grothues F, Bektas H, et al. Results of portal thrombectomy and splanchnic thrombolysis for the surgical management of acute mesentericoprotal thrombosis. Br J Surg. 1997;84(1):129-132.
65. Langnas AN, Marujo C, Stratta RJ, et al. A selective approach to preexisting portal vein thrombosis in patients undergoing liver transplantation. Am J Surg. 1992;163:132-136.
66. Inahara T. Acute superior mesenteric venous thrombosis treatment by thrombectomy. Ann Surg. 1971;174;:956-961.
67. Kazmers A. Operative management of acute mesenteric ischemia. Ann Vasc Surg. 1998;12:187-197
68. Sehgal M, Haskal ZJ. Use of transjugular intrahepatic portosystemic shunts during lytic therapy of extensive portal splenic and mesenteric venous thrombosis: long-term follow-up. JVIR. 2000;11:61-65
69. Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol. 2005;16:651-661.
70. Kim HS, Patra A, Khan J, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radilo. 2005;16:1685-1691.
71. Safieddine N, Mamazza J, Common A, et al. Splenic and superior mesenteric artery thrombolytic infusion therapy for acute portal and mesenteric vein thrombosis. J Can Chir. 2007;50(1):68-69
72. Haskal ZJ, Edmond J, Brown R. Mesenteric venous thrombosis. N Engl J Med. 2002; 346:1252-1253.
73. Ludwig DJ, Hauptmann E, Rossoff, et al. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg. 1999;30:511-554.
74. Antoch G, Taleb N, Hansen O, et al. Transarterial thrombolysis of portal and mesenteric vein thrombosis: a promising alternative to common therapy. Eur J Endovasc Surg. 2001;21:471-472.
75. Aytekin C, Boyat F, Kurt A, et al. Catheter-directed thrombolysis with transjugular access in portal vein thrombosis secondary to pancreatitis. Eur J Radiol. 2001;39:80-82
76. Ciecarelli O, Goffette P, Laterre PF, et al. Transjugular intrahepatic portosystemic shunt approach and local thrombolysis for treatment of early posttransplant portal vein thrombosis. Transplantation. 2001;72:159-161.
1. CrippaL,Vigano S,Angelo D, et al. The Utility and Cost-Effectivieness of D-dimer Measurements In The Diagnosis of Deep Vein Thrombosis. Haematologica 1997;82:446-451.
2. Reber G, Bounameaux H, Peerier A, et al. Performances of a new,automated latex assay for the exclusion of venous thromboembolism. Blood Coagulation and Fibrinolysis 2001,12:217-220.
3. Villla P, Ferrando F, Serra J,et al.Quantification of D-dimer using a new fully automated assay: its application for the diagnosis of deep vein thrombosis. Haematologica 2000,85:520-524.
4. Fukuda T, Kasai H, Kusano T, et al. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. Thromb Res2007:120(5):695-701.
5. Robert C. Gosselin, John t. Owings, Joshua Kehoe, et al. Comparison of six D-dimer methods in patients suspected of deep vein thromosis. Blood Coagulation and Fibrinolysis2003,14(6):545-550
6. Scarvelis D , Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ.2006,175(9):1087-1092.
7. Yamki T,Noxaki M ,Sakurai H ,et al. Prospective evaluation of a screening protocol to exclude deep vein thrombosis on the basis of a combination of quantitative D -dimer testing and pretest clinical probability score [J].J A M Coll Surg , 2005 ,201(5):701—709.
8. Cogo A, Lensing AW, Koopman MW, et al. Compression ultrasongraphy for diagnostic management of patients with clinically suspected deep vein thrombosis:prospective cohort study. BMJ1998;316:17-20.
9. Goodacre M, Stevenson M, Wailoo A, et al. How should we diagnose suspected deep-vein thrombosis? QJM2006;99:377-388.
10. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Annals of Family Medicine.2007;5(1):63-73.
11. Engelhardt W, Palareti G, Legnani C, et al. Comparative evaluation of D-dimer assays for exclusion of deep venous thrombosis in symptomatic outpatients. Thrombosis Research.2003;112:25-32.
12. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. Journal of Thrombosis and Thrombolysis.2008;25(1):37-44
13. Carrier M , Wells PS , Rodger MA. Excluding pulmonaryembolism at the bedside with low pre-test probability and D-dimer : Safety and clinical utility of 4 met hods to assign pre-test probability[J ] . Thromb Research , 2006 ,117 (4) :469-474.
14. Kearon C. Diagnosis of pulmonary embolism. CMAJ2003;168(2)183-194.
15. Elias A , Cazanave A , Elias M ,et al . Diagnostic management of pulmonary embolism using clinical assessment , plasma D-dimer assay , complete lower limb venous ultrasound and helicalcomputed tomography of pulmonary arteries. A multicent reclinical outcome study[J ] . Thromb Haemost , 2005 ,93 (5) :982-988.
16. Righini M; Aujesky D, Roy PM , et al. Clinical usefulness of D-dimer depending on clinical probability and cutoff value in outpatients with suspected pulmonary embolism. Arch Intern Med 2004; 164: 2483-2487.
17. Kearon C,. Ginsberg JS, Douketis J, et al. An evaluation of D-Dimer in the diagnosis of pulmonary embolism. A randomized trial. Annals of Internal Medicine, 2006,144(11):812-821.
18. Gal GL, Righini M, Roy PM, et al. Value of D-Dimer Testing for the Exclusion of Pulmonary Embolism in Patients With Previous Venous Thromboembolism. Original Investigation. 2006;166:176-180.
19. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation, 1992,86:195.
20. Toss H, Lindahl B, Siegbahn A, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation1997;96:4204-4210.
21. Danesh J , Whincup P , Walker M , et al. Fibrin D-dimer and coronary heart disease : prospective study and meta-analysis. Circulation , 2001 ,103 :2323 - 2327.
22. Stott DJ, Spilg E, Campbell AM, Rumley A, et al. Haemostasis in ischaemic stroke and vasvular dementia.Blood Coagulation and Fibrinolysis 2001, 12: 651-657.
23. Hoffmeister HM, Jur M,Wemdel HP , et al . Alterations of coagulation and fibrinolytic and kallikreinkinin systems in the acute and postacute phase in patients with unstable angina pectoris[J ] . Circulation , 1995 ,91 :2520-2527.
24. Ageno W, Finazzi S, Steidl L, et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes [ J] .Arch Intern Med, 2002, 162: 2589- 2593.
25. Koch HJ, Horn M, Bogdahn U, et al. The relationship between plasma D-dimer concentrations and acute ischemic stroke subtypes. Journal of Stroke and Cerebrovascular Diseases,2005;14(2)75-79.
26. Fujii Y,Takeuchi S , Harada A , et al . Hemostatic activation in spontaneous intracerebral hemorrhage[J ] . Stroke ,2001 ,32 :8832890.
27. Koch HJ, Uyanik G, Bogdahn U, et al. Relaion between laterality and immune response after acute cerebral ischemia. Neuroimmuomodulation2006;13:8-12.
28. Dinisio M, Rutjes AWS, Buller H. Combined use of clinical pretest probability and D-dimer test in cancer patients with clinically suspected deep venous thrombosis. Journal of Thrombosis and Haemostasis,2005;4:52-57.
29. Altiay G, Ciftci A, Demirt M. et al. High plasma d-dimer level is associated with decreased survival in patients with lung cancer. Clinical Oncology2007;19:494-498.
30. Kim HK, Lee KR, Yang JH, et al. Plasma levels of d-dimer and soluble fibrinpolymer in patients with hepatocellular carcinoma: a possible predictor of tumor thrombosis. Thrombosis research.2003,109:125-129.
31. Blackwell K, Haroon Z, Braadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. Journal of Clinical Oncology2000;18(3):600-608.
32. Kruskal JB , Robson SC , Franks JJ , et al. Elevated fibrin related and fibrinogen related antigens in patients with liver diseases. Hepatology, 1992 ,16 :920-923.
33. Spadaro A, Tortorella V, Morace C, et al. High circulating d-dimer are associated with ascites and hepatocellular carcinoma in liver cirrhosis. World J Gastroenterol 2008;14(10):1549-1552.
34. Primignani M, Dell’Era A,et al. High-d-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Digestive and Liver Disease, 2008:1238
35. Nijkeuter M, Ginsberg JS and Huisman MV. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. Journal of thrombosis and haemostasis 2006;4:496-500.
36. Kline JA, Williams GW, and Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Hemostasis and Thrombosis2005;51:825-829.
37. Eldor A. The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. European Journal of Obstetrics and Gynecology and Reproductive Biology 2002;104:3-13.
38. Ian A.Greer.Venous thromboembolism and anticoagulant therapy in pregnancy. Gender Medicine.2005;2supplement A:S10-S17.
39. Ian A.Greer. Prevention of venous thromboembolism in pregnancy. Best Practice and Research Clinical Haematology.2003;16(2):261-278.
40. Ohlmann P, Faure A. Diagnostic and prognostic value of circulating D-Dimers in patients with acute aortic dissection. Crit Care Med,2006,34, (5):1358-1364.